	r.le	
-	Reed	
1	SUPERIOR COURT O	
2	♣ .	
3	SAMUEL ALBERT REED, O	
4	Plaintiff W	
5	vs.	
6) 96-050750	
7	PHILIP MORRIS INCORPORATED,)	
8	Defendant)	
9	*********	
LO		
11		
12	Deposition of STEPHEN THOMAS JONES,	
13	taken on Tuesday, April 22, 1997, at 10:05 a.m.,	at
L 4	the law offices of Arnold & Porter, 555 12th	
15	Street, N.W., Washington, D.C., before E. Duane	
16	Smith, Notary Public.	
17		
18		
19	THE REALTIME REPORTING GROUP, INC. (410) 752-1733	œ
20	Reported by:	24
21	E. Duane Smith, RPR-CRR	8063

1	SUPERIOR	COURT OF T	THE DISTRICT OF COLUMBIA	
2				
3	SAMUEL ALBERT I	REED,)	
4	Pla	intiff)	
5	vs.) CIVIL ACTION NO.	
6) 96-050750	
7	PHILIP MORRIS	INCORPORAT	'ED,)	
8	Defe	endant)	
9				
10				
11				
12	Dep	osition of	STEPHEN THOMAS JONES,	
13	taken on Tuesda	ay, April	22, 1997, at 10:05 a.m.,	at
14	the law office	s of Arnol	ld & Porter, 555 12th	
15	Street, N.W.,	Washington	n, D.C., before E. Duane	
16	Smith, Notary	Public.		
17				
18			,	
19	THE R		EPORTING GROUP, INC.	œ
20	Reported by:	(410)	, 132 1133	7 4
21	E. Duane Smith	, RPR-CRR		20
				6

Ţ	APPEARANCES:
2	
3	
4	MARC Z. EDELL, ESQUIRE
5	Edell & Associates
6	1776 On The Green
7	Morristown, New Jersey 07962
8	
9	
L 0	JOHN C.M. ANGELOS, ESQIURE
L1	J. ROBERT WARREN, II, ESQUIRE
L 2	Law Offices of Peter Angelos
L 3	210 W. Pennsylvania Avenue
L 4	Towson, Maryland 21204
L 5	On behalf of the Plaintiff
16	
17	
18	
19	
2 0	
21	

82480635

1	(APPEARANCES CONTINUED)	
2		
3	GARY R. LONG, ESQUIRE	
4	CRAIG E. GUSTAFSON, ESQUIRE	
5	Shook, Hardy & Bacon, P.C.	
6	One Kansas City Place	
7	1200 Main Street	
8	Kansas City, Missouri 64105-2118	
9	On behalf of Defendant	
10	Lorillard, Inc.,	
11	Lorillard Tobacco Company	
12	Loews Corp.	
1.3		
14	JACK LIPSON, ESQUIRE	
15	DARRYL W. JACKSON, ESQUIRE	
16	Arnold & Porter	
17	555 12th Street, N.W.	
18	Washington, D.C. 20004-1202	
19	On behalf of Defendant	
20	Phillip Morris, Inc.	
21		ν. α
		4 0 0
		063
		8

1	(APPEARANCES CONTINUED)	
2		
3	STEPHEN P. VAUGHN, ESQUIRE	
4	Skadden, Arps, Slate,	
5	Meagher & Flom, LLP	
6	1440 New York Avenue, N.W.	
7	Washington, D. C. 20005-2111	
8	On behalf of Defendant	
9	Unites States Tobacco Company	
10	UST, Inc.	
11		
12	ROGER A. HIPP, ESQUIRE	
13	Jones, Day, Reavis & Pogue	
14	North Point	
15	901 Lakeside Avenue	
16	Cleveland, Ohio 44114	
17	On behalf of Defendant	
18	R.J. Reynolds Tobacco Company	
19	RJR Nabisco, Inc.	
20		
21		i
		(
		Ì

1	STIPULATION
2	It is stipulated and agreed by and
3	between counsel for the respective parties that the
4	filing of this deposition with the Clerk of Court
5	is hereby waived.
6	*****
7	STEPHEN THOMAS JONES,
8	being first duly sworn to tell the truth, the whole
9	truth, and nothing but the truth, testified as
L O	follows:
L 1	EXAMINATION BY MR. EDELL:
L 2	Q. Dr. Jones?
L 3	A. Yes, sir.
L 4	Q. We introduced ourselves before the
15	deposition began. My name is Marc Edell. I'm an
16	attorney participating with the plaintiffs in this
17	Reed case. Your name has been furnished to us
18	together with an affidavit indicating that you are
19	going to be an expert in this case. Do you
20	understand that?
21	A. Yes, sir.
	80
	6 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
	ω

- 1 Q. Have you ever had your deposition taken
 2 previously?
 3 A. Yes, sir.
- 4 Q. And in what matters?
- 5 A. Long time ago, a matter, an
- 6 international matter with the Brown & Williamson,
- 7 B.A.T., and Philip Morris.
- 8 Q. What kind of case was it?
- 9 A. After we sold our international
- 10 business, it was an argument between the two
- 11 companies that were left. I don't remember the
- 12 details.
- 13 Q. After we sold?
- 14 A. Lorillard, in 1977, to it was shortly
- 15 after that.
- 16 O. Sold its international business?
- 17 A. International trademarks to B.A.T. and
- 18 Brown & Williamson.
- 19 Q. You have had time to prepare for this
- 20 deposition and meet with attorneys?
- 21 A. Yes, sir.

torneys? 2480639

- 1 Q. Understand that the testimony that you
- 2 give here today can be used in a variety of ways?
- A. Yes, sir.
- Q. Do you understand that you are not to
- 5 answer any questions unless you know the answer to
- 6 the question and you understood the question?
- 7 A. Yes, sir.
- 8 Q. If you don't understand any of my
- 9 questions, please tell me and I'll rephrase the
- 10 question, right?
- 11 A. Yes.
- 12 Q. If at any juncture you want to refer to
- a document to refresh your memory with respect to
- 14 any particular fact, please feel free to ask your
- 15 attorney or me if I have a document to look at it,
- 16 okay?
- 17 A. Yes, sir.
- 18 Q. Your expertise is in the area of
- 19 chemistry; is that correct?
- 20 A. Primarily product development. I'm a
- 21 chemist by training.

- 1 Q. Your graduate degree is in what?
- 2 A. Organic chemistry.
- 3 Q. Organic chemistry. Can you draw for us
- 4 the chemical structure of nicotine?
- 5 A. Yes. I think I can.
- 6 Q. Excuse me?
- 7 A. I can come close. I'm not absolutely
- 8 positive.
- 9 Q. Let me see if I can save you a little
- 10 time.
- 11 A. To the answer is no. I can't.
- 12 Q. How is that?
- 13 A. I was close.
- Q. Does that look like nicotine to you?
- 15 A. Yes. I was almost there.
- 16 O. We have shown the witness P-16 for
- 17 identification. Doctor, can you tell us what is
- 18 depicted in P-16?
- 19 A. It is the structure in writing of the
- 20 molecule of nicotine.
- Q. Are there any cigarettes that have been

- 1 manufactured and sold to the public by Lorillard,
- 2 which don't contain nicotine?
- A. No, sir.
- 4 Q. Are there any cigarettes that have been
- 5 manufactured and sold to the public by Lorillard,
- 6 which contain a structure, a nicotine structure,
- 7 other than that depicted in P-16?
- 8 A. Not to my knowledge.
- 9 Q. All the cigarettes manufactured and sold
- 10 to the public by Lorillard have contained nicotine
- 11 that is of the same chemical structure; is that
- 12 correct?
- 13 A. Yes, sir.
- 14 Q. What is the pharmacological agent that
- is in cigarettes that affects the human body?
- 16 A. I'm not an expert in pharmacology, but
- 17 nicotine is an important compound in that regard.
- 18 Q. Is there any difference in -- let me
- 19 back up a bit. A person who smokes cigarettes
- 20 receives the nicotine through the particulate phase
- 21 of the smoke; is that correct?

- 1 A. Yes, sir.
- Q. And does the particulate phase of any of
- 3 the cigarettes that have been manufactured by
- 4 Lorillard differ with respect to the amount of
- 5 nicotine?
- 6 A. In terms of the amount of nicotine, yes.
- 7 Q. In terms of the actual composition of
- 8 the chemical nicotine, does it differ in any way?
- 9 A. I don't think to. There is a
- 10 possibility of the nicotine that acts as a salt and
- 11 the nicotine that is free could be different in
- 12 some way.
- 13 Q. I want to know what you do know and
- 14 don't know. You are the expert. I'm not the
- 15 expert.
- 16 A. I don't know that there is any
- 17 difference.
- 18 Q. And does the nicotine that is contained
- in the particulate phase of any of the smoke
- 20 produced by any of the cigarettes manufactured by
- 21 Lorillard affect the smoker in any different way?

82480643

248064

- 1 A. I don't understand the question.
- Q. In other words, let me back up a little
- 3 bit.
- 4 Why is it that Lorillard has not sold
- 5 any cigarettes that do not contain nicotine?
- 6 MR. LONG: I will object. That is very
- 7 broad. You can take a shot at it, if you want.
- A. Primarily, because there hasn't been a
- 9 market for the very low nicotine or nonnicotine
- 10 cigarettes. Others have tried.
- 11 Q. Has there been any market research
- 12 conducted by Lorillard to see whether or not there
- is a market for a nonnicotine cigarette?
- 14 A. Not to my knowledge.
- 15 Q. How do you know that there is not a
- 16 market for it?
- A. Because Philip Morris tried it and it
- 18 was unsuccessful.
- 19 Q. When did Philip Morris try it?
- 20 A. I don't know specifically, I know it was
- 21 during the time frame of the eighties.

- 1 Q. The eighties, and what was the
- 2 cigarette?
- A. Two are versions, if I recall, one was
- 4 called Next and one was called Merit De-Nic.
- 5 Q. How do you know it was unsuccessful?
- A. I had access to sales data which
- 7 indicated it was not successful.
- Q. Was there any attempt to determine why
- 9 it was unsuccessful?
- 10 A. Would you repeat the question?
- 11 Q. Yes. Was there any attempt to determine
- 12 why those two products that were sold by Philip
- 13 Morris were unsuccessful?
- 14 A. We conducted a test with that product
- 15 among consumers and found they didn't care for it.
- 16 Q. In what respect didn't they care for it?
- 17 A. They just didn't give it a high rating
- 18 on acceptability. They didn't like it.
- 19 Q. Did Lorillard come to any conclusions
- 20 with respect to why they did not give it any high
- 21 ratings, this panel of consumers?

- 1 A. I came to a personal conclusion.
- Q. What was that?
- A. Lack of nicotine.
- 4 Q. Lack of nicotine?
- 5 A. Yes.
- 6 Q. What, if anything, did you conclude with
- 7 respect to why it was that the absence of nicotine
- 8 affected the consumer's acceptability of these two
- 9 cigarettes?
- 10 MR. LONG: I'll object as vague and
- 11 ambiguous. Go ahead and answer, if you can.
- 12 A. My judgment, the product was too far
- 13 outside the mainstream of cigarettes available to
- 14 smokers. It was too different. They didn't find
- 15 it enjoyable.
- 16 Q. Did you come to any conclusions as to
- 17 why it was not enjoyable?
- 18 A. Nothing in addition to what I have
- 19 already stated.
- Q. Lorillard has done research with respect
- 21 to the composition of cigarette smoke, correct?

- 1 A. Correct.
- Q. Were you involved in any of that
- 3 research?
- A. Not directly, no.
- 5 Q. You were involved indirectly?
- A. I read some of the reports.
- 7 Q. Who was involved directly in that
- 8 research?
- 9 A. You want names? It was primarily what
- 10 we call the research group within R and D, product
- 11 development.
- 12 Q. If you could give us the names, that
- 13 would be helpful.
- 14 A. Jimmy Bell certainly was.
- 15 Q. I'm sorry. I missed that?
- 16 A. Jimmy Bell.
- 17 Q. Is he still with the company?
- 18 A. Yes. Alex Spears was.
- 19 Q. Is he still with the company?
- 20 A. Yes.
- 21 Q. Okay.

N

480648

- 1 A. Fred Schultz was.
- Q. Is he still with the company?
- 3 A. He is retired.
- 4 Q. Where is he retired to?
- 5 A. He lives in Greensboro, and there were
- 6 various chemists reporting from time to time to
- 7 Jimmy Bell. The only one I could think of off the
- 8 top of my head is James Morgan, still with the
- 9 company.
- 10 Q. Do you know whether or not Lorillard
- 11 determined whether or not there were any
- 12 tumor-initiating agents in a particular phase of
- 13 its products?
- A. Any tumor-initiating agents in the
- 15 particulate phase of our products?
- 16 Q. Yes.
- 17 A. That is outside of my realm of
- 18 expertise. I know compounds were identified in tar
- 19 that were said to be tumor promoting.
- Q. Let me ask you this: Were there any
- 21 tumor-initiating agents that were determined to be

 ∞

N

480649

- 1 in the smoke of Lorillard products that were not
- 2 present in the particulate phase of any other
- 3 products sold by Lorillard?
- 4 MR. LONG: Object as vague and
- 5 ambiguous. Go ahead.
- 6 Q. Do you understand the question, sir?
- 7 A. Yes. I think I do.
- 8 Q. Can you answer it?
- A. It is outside my area of expertise, but
- 10 I don't believe that would be the case.
- 11 Q. What is benzopyrene?
- 12 A. A polynuclear aromatic hydrocarbon.
- Q. Is it a tumor-initiating agent?
- 14 A. I don't know all the terminology in this
- 15 field. My recollection is that it is considered to
- 16 be a carcinogen.
- 17 Q. Is that agent not found in any of the
- 18 smoke particulate from any cigarette ever
- 19 manufactured by Lorillard?
- 20 A. The best of my knowledge, it would be
- 21 produced in any cigarette we ever made.

- Q. You will have to excuse me. How about
- 2 dimethylcrysine? Have I pronounced that correctly?
- 3 A. Yes, sir.
- Q. Pretty good for a lawyer.
- 5 MR. LONG: No question pending.
- 6 Q. What is that, sir?
- 7 A. I don't know specifically. I also
- 8 believe it is a PAH or polynuclear aromatic
- 9 hydrocarbon.
- 10 Q. Is it found in smoke particulate matter?
- 11 A. I can't say with certainty, but I
- 12 certainly believe that some chrysines are.
- 13 Q. Do you have reason to believe that it is
- 14 not contained in all of the smoke particulate
- 15 matter produced by all the cigarettes ever produced
- 16 by Lorillard?
- 17 A. The specific chemical, I can't say. The
- 18 class of chemicals I feel like they are in, I feel
- 19 they would be in all cigarettes produced. The
- 20 specific chrysine that you mentioned, I don't have
- 21 specific knowledge of the specific chemical.

- 1 Q. How about dibenz [a,h] anthracene?
- A. Similar compound to the others you
- 3 mentioned.
- 4 Q. Found in smoke particulate matter?
- 5 A. Yes. On steaks that have been
- 6 charcoaled or in emissions from automobiles.
- 7 Q. I'm not disputing that. I am talking
- 8 about smoke. You are produced here to talk about
- 9 cigarettes, correct?
- 10 A. Yes. But, again, I can't answer
- 11 specifically that molecule that is in smoke or that
- 12 class of molecules. I know with a high degree of
- 13 certainty they have been identified in tar.
- 14 Q. Do you know whether or not that
- 15 particular molecule is not found in any of the
- 16 smoke particulate matter produced by any of the
- 17 Lorillard cigarettes?
- 18 MR. LONG: Object as vague and
- 19 ambiguous.
- MR. EDELL: Sir, you can answer.
- MR. LONG: Would you read the question

- back? You had two or three negatives in there.
- Q. Do you know whether or not that
- 3 particular molecule, again, we are referring to, I
- 4 don't want to say it again, is not found in any of
- 5 the smoke particulate matter produced by any of the
- 6 Lorillard cigarettes?
- 7 A. It would be my judgment if it is in one,
- 8 it is in all of them. I don't know the specific
- 9 chemical, but the class would certainly be found in
- 10 the particulate matter of all cigarettes produced
- 11 by Lorillard.
- Q. What about benzo(B) fluoranthene, ever
- 13 hear of that?
- 14 A. No. I have not. Sure it is not
- 15 fluoranthene?
- 16 Q. It could be fluoranthene. I'm a lawyer,
- 17 not a chemist.
- 18 A. Fluoranthene. I don't have specific
- 19 knowledge of those types of molecules.
- Q. All right. We talked about
- 21 dibenzopyene, right, and the various different --

- 1 that's a class?
- A. Right.
- Q. Are you familiar with indene [123] [c,d]
- 4 pyrene?
- 5 A. Again, I'm familiar with the class of
- 6 pyrenes, not the specific molecule you are
- 7 referring to.
- Q. Is the class of pyrene found in smoke
- 9 particulate matter?
- 10 A. To my knowledge, yes.
- 11 Q. Are there any brands of cigarettes that
- 12 have ever been produced by Lorillard that do not
- 13 contain this class of molecule in their smoke
- 14 particulate matter?
- 15 A. I wouldn't think to.
- 16 Q. Are you familiar with benzo C
- 17 phenanthrene? Did I mispronounce that?
- 18 A. Phenanthrene?
- 19 Q. Yes.
- 20 A. General, general familiarity. These are ∞
- 21 a class of, in lay terms, not greatly dissimilar

- 1 chemical compounds that are reported to be in smoke
- 2 from all kinds of cigarettes.
- 3 Q. Are you familiar with chrysine?
- 4 A. Yes.
- 5 Q. What is that?
- 6 A. It is again a, I believe, a poly nuclear
- 7 aromatic hydrocarbon, not uncommon in particulate
- 8 matter.
- 9 Q. Is it found in the smoke particulate
- 10 matter of all cigarettes ever produced by
- 11 Lorillard?
- 12 A. I would think to.
- Q. Are you familiar with
- 14 DN3 methylcsrysine?
- A. Not the specific chemical, but, again,
- 16 it is a chrysine.
- Q. Do you have any reason to believe it is
- 18 not contained in any of the smoke particulate
- 19 matter of any of the cigarettes manufactured by
- 20 Lorillard?
- 21 A. No.

- 1 Q. Are you familiar with
- 2 2-methylfluoranthene?
- A. As a class, fluoranthenes, not the
- 4 specific chemicals.
- 5 Q. Is that class of chemical contained in
- 6 the smoke particulate matter of smoke produced by
- 7 Lorillard cigarettes?
- 8 A. To the best of my knowledge, yes, it
- 9 would be.
- 10 Q. Are you familiar with any brand of
- 11 Lorillard cigarettes that does not contain that
- 12 class of chemical and molecule?
- 13 A. I don't think there would be.
- Q. And do you know whether or not Lorillard
- 15 made any determination as to whether or not there
- 16 were any co-carcinogens found in particulate matter
- 17 produced by Lorillard cigarettes?
- 18 A. Again, this is outside my area of
- 19 expertise, but I know work has been conducted in
- 20 that area.
- Q. You have read that, the results?

- 1 A. I have read some reports over the
- 2 years. I don't have specific knowledge.
- 3 Q. What is pyrene? Is that a class?
- 4 A. It is a class of chemicals as well.
- 5 Q. Is that class of chemicals found in the
- 6 smoke particulate matter of cigarettes manufactured
- 7 by Lorillard?
- 8 A. I believe to.
- 9 Q. Are there any cigarettes manufactured by
- 10 Lorillard which do not contain that class of
- 11 chemical pyrene?
- 12 A. I doubt it.
- 13 Q. Same tries with respect to
- 14 methylpyrenes?
- 15 A. Yes.
- 16 Q. Fluoranthene?
- 17 A. Yes.
- 18 Q. Methylfluorthenes?
- 19 A. Yes, sir.
- Q. When you say yes, sir, you understand
- 21 that the question is whether or not it is found in

 ∞

2480657

- 1 smoke particulate matter in cigarettes manufactured
- 2 by Lorillard, and you have no reason to believe
- 3 that that particular compound is not contained in
- 4 all the smoke particulate matter produced by all
- 5 the cigarettes?
- 6 A. That's correct.
- 7 Q. Manufactured by Lorillard?
- 8 A. Yes, sir.
- 9 Q. The same is true with benzoperylene?
- 10 A. Not familiar with perylenes.
- Q. We covered benzopyrene?
- 12 A. Right.
- Q. What are catechols?
- A. A class much chemicals broadly defined
- 15 as phenyls.
- 16 Q. P-h-e-n-y-l-s?
- 17 A. Yes.
- 18 Q. Are phenyls found in particulate smoke
- 19 matter?
- 20 A. Yes.
- Q. Have they been identified as being

- co-carcinogens?
- A. I don't know. It is outside my area.
- 3 Q. You are not familiar with that?
- A. I'm familiar they are in smoke, I'm not
- 5 familiar if they are carcinogenic.
- 6 Q. You are not familiar with them being in
- 7 any documents you have seen in the Lorillard files
- 8 that suggest that have been identified as
- 9 co-carcinogens?
- 10 A. Not specifically in those regards, I
- 11 know they were discussed in memos in that regard, I
- 12 don't know. I know they are part of the
- 13 particulate matter.
- 14 Q. Are you familiar with
- 15 nitrosodimethylamine?
- 16 A. Nitrosodimethylamine; is that close?
- 17 Q. That's close.
- 18 A. Yes.
- 19 Q. What is that, sir?
- 20 A. It is a nitrogen compound that again
- 21 results from a lot of burning substances, including

- 1 tobacco.
- Q. Do you have any reason to believe it is
- 3 not found in any of the particulate matter of any
- 4 cigarettes ever produced by Lorillard?
- 5 A. I know it is. I know nitrosodiamines
- 6 are reported to be in tars.
- 7 Q. That's a whole family of chemical
- 8 compounds; is that correct?
- 9 A. That's correct.
- 10 Q. Are you familiar with carbon dioxide?
- 11 A. Yes, sir.
- 12 Q. Is carbon dioxide produced in the,
- 13 produced by burning cigarettes?
- 14 A. Yes, sir.
- 15 O. Is carbon dioxide found in the smoke
- 16 produced by Lorillard cigarettes?
- 17 A. Yes, sir.
- 18 Q. Are you aware of any cigarettes ever
- 19 manufactured by Lorillard that did not produce
- 20 carbon dioxide?
- 21 A. Not to my knowledge.

- 1 Q. Is the same true with respect to carbon
- 2 monoxide?
- 3 A. Yes, sir.
- 4 Q. That it is found in all of the, in the
- 5 smoke from all of the cigarettes ever manufactured
- 6 by Lorillard?
- 7 A. Yes, sir.
- 8 Q. Same is true with respect to nitrogen
- 9 oxides?
- 10 A. Yes, sir. I'm sure it would be.
- 11 O. Ammonia?
- 12 A. Not positive, but I'm pretty certain
- 13 there would be ammonia produced from any cigarette.
- Q. Same is true with respect to hydrogen
- 15 cyanide?
- 16 A. Yes.
- 17 Q. It is found in all cigarettes ever
- 18 manufactured by Lorillard, correct?
- 19 A. I would think to.
- Q. Hydrazine, same is true?
- 21 A. I'm not as sure of that. It is not

 ∞

2480661

```
1 unlikely, but I don't know.
```

- Q. What about formaldehyde?
- 3 A. Yes.
- 4 Q. Produced in the smoke phase of all
- 5 cigarettes ever manufactured by Lorillard?
- 6 A. Yes, sir.
- 7 Q. Acetone?
- 8 A. Yes.
- 9 Q. Same is true?
- 10 A. Yes.
- 11 Q. Acrolein? Same is true?
- 12 A. Yes, sir.
- 13 Q. I'm not even going to try this.
- 14 Acetonitrile?
- 15 A. Acetonitrate? Does it sound like that?
- 16 Q. It sounds like it is spelled.
- 17 A. That should be produced in all
- 18 cigarettes.
- 19 Q. In all cigarettes. Same is true with
- 20 respect to Pyridine, p-y-r-i-d-i-n-e?
- 21 A. Yes.

 ∞

- 1 Q. All cigarettes?
- 2 A. Yes.
- 3 Q. Of manufactured by Lorillard?
- 4 MR. LONG: You mean in the smoke?
- 5 Q. In the smoke produced by all cigarettes
- 6 ever manufactured by Lorillard?
- 7 A. I think to, yes.
- 8 Q. Same is true with respect to
- 9 3-vinylpyridine?
- 10 A. I would expect that to be the case.
- 11 Again, that is getting like some of the others.
- 12 They are essentially extensions of the basic class
- 13 of compounds.
- Q. And that's again, the ones we have been
- 15 discussing in the latter part of our discussion
- 16 from carbon monoxide on, those are contained in the
- 17 gas phase?
- 18 A. That's correct.
- 19 Q. Of the burning of cigarettes, correct?
- 20 A. Yes.
- Q. What is toluene?

- 1 A. It is a fairly simple chemical. It is
- 2 essentially benzene with a methyl group on it.
- 3 Q. Is that a suspected tumorigenic agent?
- A. That's outside my area of expertise.
- 5 Not that I am aware of. It may well be today.
- 6 Q. What is NNK?
- 7 A. I have seen the term. I don't recall
- 8 what it is.
- 9 Q. Are you familiar with anilin,
- 10 a-n-i-l-i-n?
- 11 A. Anilin?
- 12 Q. Yes.
- 13 A. Yes.
- Q. What is that?
- 15 A. Essentially a benzene derivative.
- 16 Q. Is it found in the particulate phase of
- 17 smoke produced by all the cigarettes ever
- 18 manufactured by Lorillard?
- 19 A. I would think to. I don't know with
- 20 certainty, but I believe it would be.
- Q. And what is norharmane?

- 1 A. I don't know.
- Q. Norharmane?
- 3 A. I don't know.
- 4 Q. Do you know what harmane is?
- 5 A. No, sir.
- 6 Q. Methyl quinoline?
- 7 A. Yes.
- 8 Q. What is that?
- 9 A. A class of chemicals called quinolines.
- 10 Q. What is it?
- 11 A. I don't know with certainty. I believe
- 12 them to be a aminobenzene type compounds, not that
- 13 different from the anilin, similar to the anilin we
- 14 discussed before.
- Q. Again, it is found in the particulate
- 16 phase of cigarette smoke?
- 17 A. I would suspect it to be.
- 18 Q. Do you have any reason to believe that
- 19 it is not found in the particulate smoke of all the
- 20 cigarettes ever manufactured by Lorillard?
- 21 A. No. I have no reason to believe it

- 1 wouldn't be.
- Q. Is there anything which is produced --
- 3 are there any tumor producing agents that are found
- 4 in the smoke particulate matter of any particular
- 5 brand of Lorillards that is not found in any of the
- 6 other brands?
- 7 MR. LONG: I object to the question as
- 8 vague and ambiguous.
- 9 Q. Do you understand the question, sir?
- 10 A. I have a general understanding of the
- 11 question.
- 12 Q. Can you answer it, please?
- A. Am I supposed to answer?
- MR. LONG: If you understand. If you
- 15 think you understand his question, answer it.
- Q. Answer it, please.
- 17 A. Repeat it, please.
- 18 Q. Is there anything which is produced --
- 19 are there any tumor producing agents that are found
- 20 in the smoke particulate matter of any particular
- 21 brand of Lorillards that is not found in any of the

8 2

- 1 other brands?
- MR. LONG: When you say "tumor producing
- 3 agents" you mean identified in science to his
- 4 belief? I mean --
- Q. In any way, shape or form. You don't
- 6 understand what the term "tumor agents" is?
- 7 A. Yes. I understand.
- 8 Q. Could you answer the question?
- 9 A. It is my belief that the compounds, many
- 10 of the compounds you mentioned including
- 11 polynuclear aromatic hydrocarbons and benzopyrenes,
- 12 these compounds are thought to be tumor promoting
- 13 or tumor causing.
- In my opinion, although it is not my
- 15 area of expertise, they would be in all cigarettes
- 16 produced, not one brand and not in another. Any
- 17 cigarette made from tobacco, I would expect them to
- 18 be there.
- 19 Q. Anything produced in the particulate
- 20 phase of any particular brand of Lorillards that is
- 21 not found in the other brands?

 ∞

- 1 A. Not to my knowledge.
- Q. Is there anything found in the gas phase
- 3 of any particular brand of Lorillard cigarettes
- 4 that is not also found in the gas phase of all
- 5 other cigarettes manufactured by Lorillard?
- A. Not to my knowledge.
- Q. Are there any tumor agents found in the
- 8 gas phase of -- let me back up.
- 9 Are there any additives found in any
- 10 Lorillard brand that are not contained in any other
- 11 Lorillard brand?
- 12 A. Can you be specific with respect to
- 13 "additive"?
- 14 Q. I don't know what you put in your
- 15 cigarettes, Doctor, to I can't be any more
- 16 specific.
- 17 A. Would you restate the question, please?
- Q. Are there any additives found in any
- 19 Lorillard brand that are not contained in any other
- 20 Lorillard brand?
- 21 A. Yes, sir.

24806

- 1 Q. Okay. Can you tell us what brands
- 2 contain additives that are not found in other
- 3 brands?
- 4 A. We have a line of menthol cigarettes
- 5 which have menthol. Non-menthol cigarettes do not
- 6 have.
- 7 Q. Anything else?
- 8 A. You are getting into an area I'm not
- 9 comfortable with, in terms of proprietary and trade
- 10 secrets, when you are talking about additives.
- 11 Q. You are testifying as an expert
- 12 witness.
- MR. LONG: We have been negotiating a
- 14 protective order, Craig has talked with John --
- MR. GUSTAFSON: John and Rob.
- MR. LONG: We explained our position
- 17 that if the depositions go forward without a
- 18 protective order in place, there may be areas we
- 19 are not going to let the doctor testify about as
- 20 proprietary. We discussed that. If you want to
- 21 get into general areas, and if Dr. Jones can answer

- 1 questions without in his opinion getting into
- 2 proprietary information by giving ranges or
- 3 something of that nature, that's fine. We are not
- 4 going to sit here and talk about recipes and things
- 5 of that nature without a protective order.
- 6 MR. EDELL: I don't want to know
- 7 quantity or recipe, I am asking him for him to
- 8 identify additives, that's all. Is that still
- 9 proprietary?
- MR. LONG: I will have to ask him.
- 11 MR. EDELL: Take a break and ask him.
- 12 Go ahead. We'll take a short break.
- 13 (Break.)
- MR. EDELL: Mr. Long?
- 15 MR. LONG: We're not going to allow
- 16 Dr. Jones to testify about additive ingredients,
- 17 because the area is to much in proprietary
- 18 information.
- 19 MR. EDELL: To the record is clear, it
- 20 is my understanding from speaking with my
- 21 co-counsel who are more familiar with the rules in

- 1 the Superior Court of the District of Columbia than
- 2 I, that it is your obligation to obtain a
- 3 protective order in the first instance. You
- 4 haven't done that. You have produced him here as
- 5 an expert witness to talk about the difference
- 6 between various cigarettes that have been
- 7 manufactured by Lorillard over the years. It is
- 8 our position that if you direct him not to answer
- 9 these questions, that similarly, he should be
- 10 precluded from offering any expert testimony on the
- 11 difference between the cigarettes manufactured by
- 12 Lorillard.
- To I don't want you to be surprised at
- 14 some later juncture. I'm also willing to go
- 15 forward in this narrow area and exclude your
- 16 competitors, with the understanding that whatever
- 17 is said will be maintained under seal.
- 18 MR. LONG: First of all, if you can find
- 19 something in his affidavit about ingredients, that
- 20 is one issue.
- 21 MR. EDELL: All right. We'll do that.

 ∞

```
1
                MR. LONG: Secondly, I was not in on the
     discussions either, but I understand that
 2
 3
     Mr. Gustafson had discussions with some of your
     co-counsel, pointed out we didn't have a protective
     order, we would continue to work on one. Did we
 5
     suggest putting the deposition off until that was
     resolved?
 7
                MR. GUSTAFSON: Not specifically, we
 8
     talked about putting it off to the 28th or 30th,
 9
     which would have given us more time to negotiate a
10
    protective order. That was mentioned, but it was
11
     not agreed upon. I make my --
12
                MR. EDELL: As I understand it, we have
13
     certain briefing schedules, everything is tied to
14
     everything else, to we are not at liberty to extend
15
16
     the period to that we can come to some agreement.
     If we can't come to agreement, I believe that the
17
     law imposes the duty on you, if you are going to
18
19
     affirmatively assert him or offer him as an expert
     witness to get a protective order. As I said, I'm
20
21
     willing to enter into an agreement whereby we
```

- 1 exclude your competitors from the room, and this
- 2 portion of the testimony will be maintained under
- 3 seal.
- 4 MR. LONG: We had discussed this, and I
- 5 understand that the possibility that this area
- 6 might come up, we have discussed with some of
- 7 Mr. Edell's co-counsel.
- 8 MR. GUSTAFSON: Rob and I and John both
- 9 discussed the fact that confidential and trade
- 10 secret matters may arise during the deposition. I
- 11 told them quite candidly if those issues arose, we
- 12 couldn't allow him to testify without the
- 13 protective order in place. We talked about, and,
- in fact, I faxed a protective order from another
- 15 case and, in fact, the parties are near agreement
- on a protective order in the Maryland AG case. The
- 17 bottom line is we didn't agree upon the protective
- 18 order prior to this deposition, but certainly you
- 19 were put on notice, and in the affidavit of
- 20 Mr. Jones, there is no information there regarding
- 21 additives or ingredients. To I don't think this

- 1 line of questioning is even relevant to his
- 2 affidavit.
- 3 MR. LONG: Bottom line, Marc, is your
- 4 people knew and our people knew that we were trying
- 5 to proceed with the schedule, we didn't think that
- 6 additives and ingredients would be an issue. If
- 7 they were, they are trade secrets problems and we
- 8 discussed it with your people. If you say you
- 9 shouldn't have brought him without the protective
- 10 order, let's stop the deposition, go get a
- 11 protective order sometime and come back.
- 12 MR. EDELL: As I understand it, there
- 13 was a difference in terms of what your position was
- 14 on this protective order from what our position
- 15 was, I wasn't participating in it, if we could not
- 16 reach an accord, I think the law places an
- 17 obligation on you to obtain a protective order.
- MR. LONG: Let's don't do the deposition
- 19 until we get one. My understanding was that your
- 20 people in good conscious and faith with my people
- 21 discussed this possibility. We were hoping that

- 1 something could be resolved, something was going on
- 2 in the AG case that you were involved in, that was
- 3 our understanding, but to come in here and say we
- 4 didn't reach one, you can't claim anything, I think
- 5 is a little bit misguided given the discussions
- 6 between the two sides.
- 7 MR. EDELL: The court will interpret all
- 8 of this the way it interprets it. I certainly can
- 9 work around the additive issue now, and we can
- 10 isolate that issue for the court's decision.
- 11 MR. LONG: Okay. That's fine.
- MR. EDELL: In any event --
- Q. Are there any cigarettes that produce
- 14 any tumorigenic or other harmful agents in the gas
- 15 phase of, in their gas phase, that are not produced
- 16 by all of the Lorillard cigarettes?
- 17 MR. LONG: I'll object again. You keep
- 18 referring to tumorigenic, I mean there are tests
- 19 that have shown in animals --
- MR. EDELL: I'll withdraw the question
- 21 then.

- 1 Q. Would you agree that all tobacco
- 2 products manufactured by Lorillard contain amounts
- 3 of nicotine?
- 4 A. Yes.
- 5 Q. Would you agree that all tobacco
- 6 products manufactured by Lorillard have similarly
- 7 contain other alkaloids?
- 8 A. Yes. There are other alkaloids present
- 9 in tobacco.
- 10 Q. Would you agree that nicotine is
- 11 absorbed from tobacco smoke into the lungs of
- 12 smokers?
- 13 A. This is again outside my area of
- 14 expertise, but certainly I would think to, from
- 15 what I have read, yes. I'm not an expert in this
- 16 area.
- 17 Q. What area of expertise do you visualize
- 18 this encompassing, this question I just asked?
- 19 A. Probably pharmacology and toxicology.
- Q. Who at Lorillard is an expert in that
- 21 area?

8248067

- 1 A. In toxicology?
- Q. On pharmacology and toxicology insofar
- 3 as it pertains to my questions that I just posed on
- 4 nicotine?
- 5 A. I don't think we have a pharmacologist
- 6 on staff. We do have a, at least one toxicologist,
- 7 perhaps more than one. Dr. Dan Hecht is a
- 8 toxicologist.
- 9 Q. Are you familiar with nicotine and its
- 10 affects on human beings?
- 11 A. I've read things in the literature, I'm
- 12 not an expert in nicotine pharmacology, by any
- 13 means. I'm certainly aware of literature, press.
- 14 Q. How many years have you been in the
- 15 research and/or product development department of
- 16 Lorillard?
- 17 A. Been with the company 28 years, all of
- 18 which were not in that department, but a
- 19 significant portion has been.
- 20 Q. Have you ever participated in the design
- 21 of any cigarettes?

 ∞

- 1 A. Yes, sir.
- Q. Which cigarettes?
- A. Are you referring to new brands or
- 4 revisions to existing brands?
- 5 Q. All of the above.
- 6 A. I participated in the design of Newport
- 7 as it is sold today, Kent Golden Lights, Kent III,
- 8 Triumph, Maverick, Style.
- 9 Q. That was a big one?
- 10 A. Still selling some. Versions of Old
- 11 Gold, Max, probably some involvement with
- 12 practically all the brands we sell today.
- Q. Was nicotine ever at issue with respect
- 14 to the design or revision of any of these brands?
- MR. LONG: Objection. Vague and
- 16 overbroad.
- 17 A. Does this mean I answer or don't
- 18 answer?
- MR. LONG: You can answer, if you
- 20 understand what he is asking?
- 21 A. Only from the standpoint that we had

- 1 parameters for new brands which included tar and
- 2 nicotine deliverance.
- Q. Who provided those parameters with
- 4 respect to nicotine?
- 5 A. Generally the marketing department for a
- 6 new brand. It wouldn't be nicotine in isolation.
- 7 We would be asked to develop a product in a
- 8 particular category with a tar and nicotine
- 9 delivery.
- 10 Q. What do you mean by a particular
- 11 category?
- 12 A. We view the U.S. industry as being made
- 13 up of categories.
- Q. What categories are those?
- 15 A. Nonfilter cigarettes, full-flavor
- 16 cigarettes, light cigarettes, ultra-light tar
- 17 cigarettes.
- 18 Q. When you say "we" you are talking about
- 19 Lorillard?
- 20 A. Yes.
- 21 Q. To we have --

 ∞

- 1 A. It is generally categorized by the
- 2 industry. The terms may not be identical, but they
- are generally referred to this way in the industry.
- 4 Q. As nonfilter, full-flavor, light and
- 5 ultra-low?
- 6 A. Yes. Sometimes light and low-tar are
- 7 used interchangeably.
- 8 Q. How do you define the nonfilter
- 9 category?
- 10 A. They are cigarettes which don't include
- 11 a filter as a part of the design.
- 12 Q. How do you define the full-flavor
- 13 category?
- 14 A. Generally those products that deliver
- 15 more than 15 milligrams of tar.
- 16 Q. More than?
- 17 A. 15 milligrams of tar generally.
- 18 Q. How do you define the light category?
- 19 A. Generally those brands that deliver
- 20 seven milligrams of tar, but less than 15.
- 21 Q. How do you define the ultra-low

- 1 cigarette?
- 2 A. Those that deliver 6 or fewer milligrams
- 3 of tar.
- Q. What's your understanding as to why it
- 5 is broken up in those four categories?
- 6 A. My understanding is for marketing
- 7 reasons historically.
- 8 Q. What do you mean by "marketing
- 9 reasons"?
- 10 A. There was a push to lower tar cigarettes
- 11 in the seventies, and a category developed and we
- 12 put a name on it.
- Q. Nicotine is the, one of the parameters
- 14 that define these categories; is that correct?
- 15 A. Primarily, it is tar. Nicotine is
- 16 attendant, but primarily the tar categories, we
- 17 rarely refer to a nicotine, when we are talking
- 18 about a category. Generally we refer to tar.
- 19 O. It is not tar and nicotine that define
- 20 the categories?
- 21 A. The term is used, but when we look at it

- in development, we talk about tar categories, not
- 2 tar and nicotine.
- 3 Q. Has it ever been part of the parameters
- 4 that you have been given that you should explore
- 5 the possibility of enhancing the effect of
- 6 nicotine?
- 7 A. I'm not sure I quite understand. There
- 8 have certainly been efforts to enhance the delivery
- 9 of nicotine. The effect is, you are getting into
- 10 an area in which I have no expertise again.
- 11 Q. What do you mean by "enhance the
- 12 delivery of nicotine"?
- 13 A. There are pressures on the industry from
- 14 government sources and everybody else, some years
- 15 ago, to reduce tar, and at the same time, we were
- 16 being told to make the nicotine higher and get the
- 17 tar down, to we did a lot of work in that area.
- 18 Q. You are not familiar with any efforts by
- 19 Lorillard to enhance the effects of nicotine in any
- 20 of its cigarettes; is that correct?
- MR. LONG: I object as vague and

248068

- 1 ambiguous. He explained what he didn't understand
- 2 about your question earlier, and you have asked it
- 3 exactly the same way.
- 4 Q. Let me make sure I am using the term
- 5 correctly. While I am looking at this, what is a
- 6 super hi-fi category?
- 7 A. That was an old term that pretty much
- 8 became ultra-low tar, it was just a term that we
- 9 used and it evolved into ultra light tar over the
- 10 years. It meant super high filtration or highly
- 11 filtered, which is characteristic of ultra low tar
- 12 cigarettes in general.
- 13 MR. EDELL: I'm glad you objected to the
- 14 question, counsel, because I was using the wrong
- 15 phrase.
- 16 Q. The phrase is enriching the nicotine.
- 17 Have you ever made an effort to enrich the nicotine
- in any cigarettes manufactured by Lorillard?
- 19 A. Made efforts in the laboratory, yes.
- 20 Q. What is your understanding of efforts
- 21 made by Lorillard to enrich the nicotine in the

- 1 laboratory?
- A. You want a broad answer? Be more
- 3 specific.
- 4 Q. Give me the broad answer and I'll be
- 5 more specific.
- A. A lot of efforts to doing just that,
- 7 none of which were applied commercially, to my
- 8 knowledge.
- 9 Q. Tell me about the efforts that you are
- 10 referring to.
- 11 A. We tried adding nicotine to the tobacco
- 12 through adding it to the burly casing.
- Q. When did you first attempt to do that?
- 14 A. I don't know specifically. My guess
- 15 would be early seventies.
- Q. Were you responsible for that project?
- 17 A. Partly, I certainly was involved in that
- 18 project.
- 19 Q. Who was the person in charge of that
- 20 project?
- 21 A. Probably my counterpart at the time. I

248068

 ∞

- 1 was a supervisor in the lab and I reported to
- 2 Charlie Tucker who is retired as director of
- 3 product development. I guess in the sense you are
- 4 asking the question, we have been in charge of the
- 5 project.
- 6 Q. When you say "the project" did it have a
- 7 name?
- 8 A. In product development we had a lot of
- 9 work in terms of trying to boost the nicotine
- 10 delivery, enrich nicotine is a term that has been
- 11 used around Lorillard, enriched flavors.
- 12 Q. I'm talking about nicotine and I want to
- 13 know the name of the first project that you recall
- 14 that involved enriching nicotine in Lorillard
- 15 products.
- 16 A. I just don't remember if we named
- 17 projects in the seventies like that. I know I
- 18 worked on enriching nicotine. We may well have
- 19 called it enhanced nicotine or nicotine
- 20 enhancement. I don't remember specifically what we
- 21 called it. But everybody knew what we were talking ∞

- 1 about.
- Q. What were we talking about?
- A. Trying to add nicotine and reduce tar,
- 4 to affect the nicotine and tar ratios in smoke.
- 5 Q. Why were you trying to do that?
- 6 A. Lot of pressure on reducing tar,
- 7 including from the government, a lot of press, that
- 8 said you need to make cigarettes with lower tar to
- 9 keep the people to enjoy the cigarettes, boost the
- 10 nicotine, to we were reacting to a lot of outside
- 11 pressures.
- 12 Q. It is not your testimony that the
- 13 government was trying to get you to boost the
- 14 nicotine?
- 15 A. It certainly wasn't unheard of in the
- 16 context of those days. Absolutely. The government
- 17 was supporting efforts to grow tobacco that had
- 18 higher nicotine than normal tobacco, and the
- 19 government was funding that.
- Q. It is your testimony that the government
- 21 was pressuring Lorillard to produce cigarettes with $^{\infty}_{N}$

- 1 enriched nicotine?
- A. I think pressure is too strong a term.
- 3 Q. That was your phrase, not mine.
- 4 A. You said it differently than I intended
- 5 it.
- 6 Q. Maybe it was just the emphasis.
- 7 A. I think certainly there was an effort to
- 8 reduce tar. That was the main thrust. The
- 9 secondary thing that came out of it said: If you
- 10 are going to reduce tar, you have to give more
- 11 nicotine to keep people smoking these low tar
- 12 cigarettes. You have to put it in the reference of
- 13 the times, in the seventies, when you didn't have
- 14 the variety or the number of smokers of lower
- 15 delivery cigarettes, to, yes, in that sense, there
- 16 was a pressure or a call to work in that regard and
- 17 we certainly did.
- 18 Q. It is your testimony that the government
- 19 created this pressure that resulted in your efforts
- 20 to develop an enriched nicotine cigarette?
- 21 A. I don't think it was only the

- 2 the area. It was just thought to be an avenue that
- 3 should be pursued in that time. It wasn't solely
- 4 the government. They certainly were a party to it.
- 5 Q. The government was a party to your
- 6 adding, attempting to add nicotine to your
- 7 products?
- 8 A. I think to.
- 9 Q. Who in the government was involved in
- 10 that process?
- 11 A. I don't know, sir.
- 12 Q. What is the basis for your statement?
- 13 A. Memory of what was going on at the time.
- Q. Factually, where do you get that?
- 15 A. Factually, I can't give you an answer as
- 16 to the specific person.
- 17 Q. Can you give me an agency?
- 18 A. No. I know the agronomy group at N.C.
- 19 State and the extension services, both of whom got
- 20 government funding were active in the area. I have
- 21 a recollection of making some of these cigarettes

 ∞

- 1 with these tobaccos for the National Cancer
- 2 Institute. I don't remember the names of the
- 3 specific people. That's more than 20 years ago.
- Q. It is your testimony that you made
- 5 cigarettes with enhanced nicotine contents, that is
- 6 adding content for NCI; is that correct?
- 7 A. That is not correct.
- 8 Q. What did you say?
- 9 A. I said I made cigarettes from tobaccos
- 10 that were bread to have a higher nicotine-to-tar
- 11 ratio. That is different from my having added
- 12 nicotine to cigarettes and sent it to NCI. I did
- 13 not say that.
- 14 Q. It is your testimony with respect to the
- 15 project where you were exploring the possibility of
- 16 adding nicotine to Lorillard cigarettes, prototypes
- 17 of those cigarettes were never furnished to NCI; is
- 18 that correct?
- A. Not to my knowledge, they were not.
- Q. Tell us how Lorillard was attempting to
- 21 add nicotine to their cigarettes?

- 1 A. One avenue I just mentioned was adding
- 2 nicotine to the burly casing.
- 3 Q. How would you do that?
- A. A liquid formulation, flavors that are
- 5 spread on, years ago, burly may have been dipped in
- 6 the additive, what you may be familiar with as
- 7 casing solution, that is one avenue.
- 8 Q. Where do you get the nicotine from?
- 9 A. We bought some nicotine in that time
- 10 frame from a chemical or a flavor house, I don't
- 11 remember specifically whom. I remember purchasing
- 12 it.
- 13 Q. Somehow would it be delivered?
- 14 A. Smaller quantities could be purchased in
- 15 any chemical supply firm.
- 16 Q. How were they delivered, how was this
- 17 nicotine delivered?
- 18 A. To us from a supplier?
- 19 Q. Yes.
- 20 A. Small amounts would be in a bottle, a
- 21 liter, or down to the size of a Coke bottle there.

 ∞

2480690

- 1 Q. What about large orders?
- 2 A. The biggest I recall was one 55-gallon
- 3 drum.
- 4 Q. Did the people in marketing ever ask for
- 5 you to develop an enriched nicotine cigarette?
- 6 A. I'm not sure they asked for it
- 7 specifically in that manner. They certainly asked
- 8 for us to develop low tar cigarettes. We in
- 9 product development probably attempted to do it
- 10 through that method. I'm not sure that marketing
- 11 ever asked for enriched nicotine, per se.
- 12 Q. You remember Lorillard working with MCA
- 13 Graham Advertising?
- 14 A. Yes.
- 15 Q. Developing their five-year plan?
- 16 A. I have some recollection.
- 17 Q. You participated in that process in the
- 18 late 1970s, correct?
- 19 A. I'm sure I did, I have off and on over
- 20 the years.
- Q. Do you recall, let me see if I can get

- 1 the document for you. I got to find out what we
- 2 marked it as. It is June 12, 1979.
- 3 I'll show you what we have marked as
- 4 Plaintiff's Exhibit No. 73. Does that document
- 5 refresh your recollection in any way, sir, with
- 6 respect to your participation of a five-year plan
- 7 involving MCA Graham Advertising?
- 8 A. May I take the time to read it?
- 9 Q. Absolutely. Take as much time as you
- 10 need.
- MR. LONG: This was produced in the
- 12 Texas AG case?
- MR. WARREN: I don't know.
- MR. LONG: It says produced in Texas.
- 15 If there is a protective order in Texas, you can
- 16 use this in other cases if you have a protective
- 17 order entered.
- 18 MR. WARREN: It didn't come from the
- 19 Texas AG case. I'm not sure.
- MR. LONG: It has confidential on it,
- 21 and it has protective order, I want to know whether

 ∞

82

480692

- 1 you have a protective order that you can use it
- 2 here.
- MR. WARREN: That came through --
- 4 MR. LONG: The point is you may be
- 5 violating an order in other case without a
- 6 protective order here.
- 7 MR. EDELL: That could be very bad.
- 8 MR. LONG: We need to know where you got
- 9 the document, before we start chatting about it.
- MR. EDELL: Why don't we take a short
- 11 break. We'll talk about that. I don't know where
- 12 that document came from. I will speak to my
- 13 co-counsel.
- 14 (Break.)
- 15 Q. Let's go back on the record. Dr. Jones,
- 16 we are going to go on to another area and avoid
- 17 these documents right now, because there are some
- 18 outstanding issues that have to be resolved.
- 19 Hopefully we will resolve them over the lunch
- 20 break. If we don't, then we'll figure out
- 21 something to do. Okay?

- 1 A. Yes, sir.
- Q. Are you familiar with the fact that
- 3 nicotine enters the blood and is rapidly
- 4 distributed to the brain in smokers?
- 5 A. I have a general familiarity. I believe
- 6 that to be the case. Again, it is outside my area
- 7 of expertise, but I believe that is the case.
- 8 Q. Would you agree that nicotine is a
- 9 powerful pharmacologic agent?
- 10 A. I would certainly agree it is a
- 11 pharmacologic agent, yes.
- 12 Q. Would you agree that it is the
- 13 predominant pharmacologic agent that reinforces
- 14 cigarette smoking?
- 15 A. That is again outside my area of
- 16 expertise, but my personal belief is that that is
- 17 probably the case.
- Q. Would you agree that nicotine acts on
- 19 specific binding sites or receptors throughout the
- 20 nervous system of the smoker?
- 21 A. I don't have knowledge in that area.

248069

 ∞

 ∞

248069

- 1 Q. Who at Lorillard would have knowledge in
- 2 that regard?
- A. I would think Dr. Alex Spears. Probably
- 4 Dr. Christopher Coggins, Dr. Dan Hecht.
- 5 Q. Do you know whether or not Lorillard has
- 6 done any research with respect to the effect of
- 7 nicotine on the smoker?
- A. Not to my knowledge.
- 9 Q. Have there ever been proposals to
- 10 conduct such studies?
- 11 A. I don't know.
- 12 Q. Has there ever been an attempt by
- 13 Lorillard to determine why people smoke?
- 14 A. Not to my knowledge.
- Q. Are you aware as to whether or not any
- 16 of Lorillard's competitors have ever done research
- 17 in that regard?
- 18 A. I'm not aware, no.
- 19 O. You are not aware of the research that
- 20 Philip Morris did in that regard?
- 21 A. I may have read something in the popular

- 1 press that referred to it, but I don't have any
- 2 direct recollection of it.
- Q. You don't try to keep up on the research
- 4 that is being conducted, consumer research being
- 5 conducted by your competitors?
- 6 A. Consumer research conducted by
- 7 competitors is confidential. They wouldn't let me
- 8 see it.
- 9 Q. Did you ever discuss the issue as to why
- 10 smokers smoke with anyone at Lorillard?
- 11 A. I am sure I have.
- 12 Q. With Dr. Spears?
- A. More likely colleagues in product
- 14 development. I probably have had conversations
- over the years with Dr. Spears as well.
- 16 Q. Isn't that a critical issue with respect
- 17 to product development as to, with respect to
- 18 cigarettes, to try to determine why smokers smoke
- 19 and why they keep smoking?
- 20 A. That is really not our focus in product
- 21 development.

 ∞

- 1 Q. By what area of the company would that
- 2 guestion be addressed?
- 3 A. I don't think it is relevant to what we
- 4 do.
- 5 MR. EDELL: Not relevant. Okay.
- 6 MR. LONG: When you say "we"?
- 7 THE WITNESS: The company, Lorillard.
- 8 Q. Does Lorillard sell any product other
- 9 than cigarettes?
- 10 A. No.
- 11 Q. It is your testimony that why people
- 12 smoke cigarettes and continue to smoke cigarettes
- is not a relevant issue to Lorillard?
- A. I am saying it is not an issue that we
- 15 act on.
- 16 Q. What do you mean by "it is not an issue
- 17 that you act on"?
- 18 A. I view my role in product development
- 19 and our role is to maximize our market share among
- 20 those who smoke.
- Q. Would you agree that really in essence

THE REALTIME REPORTING GROUP, INC.

82

- 1 Lorillard is selling smoke and not cigarettes?
- 2 A. No.
- Q. Who is Dr. Parmele, or is it Parmele?
- 4 A. Parmele.
- 5 Q. Who is that?
- 6 A. Retired researcher from Lorillard, I
- 7 believe he retired when I joined the company or
- 8 about that time.
- 9 Q. He was a researcher. Wasn't he the
- 10 director of research?
- 11 A. He may have been, but he wasn't when I
- 12 was with the company.
- Q. You are not familiar with his position?
- 14 A. I have seen his name around, people
- referred to Dr. Parmele, but I didn't know.
- 16 Q. Have you attended meetings of CORESTA?
- 17 A. Yes.
- 18 Q. Can you tell us what CORESTA is?
- 19 A. It is an international body of tobacco
- 20 scientists, people that are interested in tobacco,
- 21 both agronomy and technology and smoke chemistry.

- Q. And you have attended those meetings?
- 2 A. Yes.
- 3 Q. When did you begin to attend meetings of
- 4 CORESTA?
- A. My best guess would be mid seventies.
- 6 Q. Who attended those meetings prior to
- 7 your attending those meetings on behalf of
- 8 Lorillard?
- 9 A. Usually more than one person is
- 10 attending, to I did not replace someone
- 11 necessarily.
- Dr. Fred Schultz certainly went to
- 13 CORESTA meetings, Dr. Alex Spears, Dr. Norman and
- 14 Jimmy Bell that I mentioned earlier.
- Q. When you come back from these meetings,
- 16 would you, are you given materials that are handed
- 17 out at those meetings?
- 18 A. Yes.
- 19 Q. What do those materials usually consist
- 20 of?
- MR. LONG: I object. Vague and

- l ambiguous.
- A. Generally abstracts of the papers that
- 3 were presented. Sometimes reprints of the entire
- 4 presentation.
- 5 Q. What do you do with them?
- A. I generally send them to our library.
- 7 Q. Are you familiar with the presentation
- 8 that was made in October of 1972 by William Dunn?
- 9 A. No, sir.
- 10 Q. You know who William Dunn is, don't you?
- 11 A. I know the name. Don't know who he is.
- Q. Who would have been attending CORESTA
- meetings from Lorillard in 1972?
- 14 A. I can speculate it would have been
- 15 Dr. Spears and Dr. Schultz.
- Q. Do you agree with Dr. Dunn that the
- 17 cigarette should not be conceived as a product, but
- 18 as a package, and that the product is nicotine?
- 19 A. No. I don't think to.
- Q. Why do you disagree with that?
- 21 A. People smoke for a variety of reasons.

- 1 Again, we are outside my area of expertise.
- Q. I thought your area of expertise was
- 3 design; is that correct? What is your area of
- 4 expertise?
- 5 A. I think product design.
- Q. And what do you mean by "product
- 7 design"?
- 8 A. Blending. Filtration.
- 9 Q. What do you mean by blending?
- 10 A. The use of various tobacco types.
- 11 Q. Okay.
- 12 A. Which when blended together result in an
- 13 enjoyable, pleasurable cigarette.
- 14 Q. What else, blending --
- 15 A. To a lesser extent flavoring, to a
- 16 lesser extent filter development.
- 17 Q. Additives come in the flavoring aspect
- 18 of this?
- 19 A. Yes.
- Q. Any other aspect?
- 21 A. Some knowledge of manufacturing,

THE REALTIME REPORTING GROUP, INC.

 ∞

- 1 processing.
- Q. Filters, do you design the filters?
- 3 A. Not currently. I have worked in that
- 4 area a little bit in the past.
- 5 Q. When did you work in the design of
- 6 filters?
- 7 A. It was never a major responsibility, but
- 8 I have had ideas for filters that we used.
- 9 Q. Have you ever submitted a patent
- 10 application for a filter?
- 11 A. No.
- Q. You are an expert in filters?
- 13 A. I wouldn't say I'm an expert, no.
- 14 Q. Are you an expert in flavoring?
- 15 A. Not saying I'm an expert.
- Q. Are you an expert in blending?
- 17 A. I think I was at one time. I probably
- 18 am not any longer.
- 19 Q. What is your current area of expertise?
- 20 A. I am a manager. I have a group of
- 21 people that I have to manage. More of an

- 1 administrative person today.
- Q. What do you know firsthand about the
- 3 design of Lorillard cigarettes prior to 1969?
- 4 A. Almost nothing. I joined the company in
- 5 1968.
- Q. What have you reviewed to give you the
- 7 information that you needed in order to sign this
- 8 affidavit that you did in this case, regarding the
- 9 design of Lorillard cigarettes prior to 1969?
- A. I reviewed some historical FTC reports,
- 11 actual sales data.
- 12 Q. Historical FTC reports, what else?
- 13 A. Historical Maxwell data.
- Q. Can you tell us what you are talking
- 15 about?
- 16 A. The Maxwell report, it is generally --
- Q. Generally available to the public?
- 18 A. Generally available to the public.
- 19 Q. What else?
- 20 A. I reviewed some of our specifications
- 21 for filters.

- Q. Who gave you those specifications?
- A. I had a copy in my office.
- Q. I'm sorry?
- 4 A. I had a copy in my office.
- 5 Q. Which filters are you talking about?
- 6 A. I looked at all the filters that were
- 7 used, certainly, in all the filter constructions on
- 8 the, or specifications for the lower tar
- 9 cigarettes, that employed air dilution.
- 10 Q. Does that include Kent?
- 11 A. Yes.
- 12 Q. Did you have as a part of those
- 13 specifications the information with respect to the
- 14 addition of asbestos to filters in Kent cigarettes?
- 15 A. No.
- 16 Q. You are not aware that they used
- 17 asbestos in their filters during a certain period
- 18 of time?
- 19 A. I'm aware of those cases and publicity
- 20 on it. It predates me. I did not look at those
- 21 sort of documents for the purposes of this

THE REALTIME REPORTING GROUP, INC.

 ∞

- Q. Beginning at what point? You were aware
- 3 that Lorillard did use asbestos in their filters
- 4 during a certain period of time, correct?
- 5 A. Yes. I have read reports about it.
- 6 Q. During what period of time did they use
- 7 asbestos?
- 8 A. I don't know exactly.
- 9 Q. What is your understanding?
- 10 A. 50's.
- Q. Did Lorillard test its filters before
- 12 they used them insofar as you understand it?
- 13 A. I have no knowledge of what they did in
- 14 the fifties.
- 15 Q. Do you know what they did in the
- 16 sixties? Did they test the filters in the
- 17 sixties?
- 18 A. I don't understand the question about
- 19 test. Certainly we had specifications and various
- 20 parameters.
- Q. Before they sent them out the door to

- 2 testing of these filters to determine whether or
- 3 not the consumers were getting any potentially
- 4 harmful substances from the filters?
- 5 A. I have no knowledge of that kind of
- 6 work.
- 7 Q. Wasn't that part of the normal routine?
- 8 A. I have no knowledge back then.
- 9 Q. How about when you came with the
- 10 company? Was that part of their normal routine, to
- 11 conduct these?
- 12 A. After moving to product development, it
- was not part of the normal routine, to my
- 14 knowledge, which was around 1970.
- Q. What about the additives? Did they test
- 16 the additives before they would tell the product to
- 17 human beings, during the time period that you were
- 18 there?
- 19 A. Additives were relatively simple
- 20 chemical compounds. I don't know what testing was
- 21 done. Everything we used is tested to some degree

- 1 by somebody and considered to be appropriate, but
- 2 not familiar with any testing of the additives in
- 3 the way you are asking the question.
- 4 Q. I'm asking you specifically whether or
- 5 not Lorillard paid for or conducted itself research
- 6 with respect to any of the additives they ever put
- 7 in any of their product to determine whether or not
- 8 those additives were potentially harmful to the
- 9 consumers?
- 10 A. You are not restricting your question to
- 11 filters now?
- Q. Whole ball of wax, additives, filters?
- 13 A. Yes. We do tests, yes.
- 14 Q. When did you start testing the
- 15 additives?
- A. Again, this is outside my area. It is
- 17 not a product development function, but I think
- 18 probably in the early eighties.
- 19 Q. What department has as its function the
- 20 testing of these additives?
- A. It comes under the research department.

- 1 Q. I thought that you were in charge of
- 2 research and development?
- 3 A. No. Product development.
- 4 Q. Not research?
- 5 A. No.
- 6 Q. My misunderstanding. Who is in charge
- 7 of research and development?
- 8 A. Well, there are two, research and
- 9 development.
- 10 Q. Who is in charge of research?
- 11 A. Dr. Jack Reed is director of research.
- 12 Q. To he would know more than you about the
- 13 testing of these additives?
- 14 A. Yes.
- Q. But you would receive reports, wouldn't
- 16 you?
- 17 MR. LONG: Let me object a second. What
- 18 does this have to do with class certification? We
- 19 have a case management order in this case, which
- 20 limits discovery at this time to class
- 21 certification issues. You are definitely talking

- 1 about issues that go to merits.
- MR. EDELL: No. I'm talking about what
- 3 substances are found in cigarettes. You are trying
- 4 to differentiate --
- 5 MR. LONG: You are talking about testing
- 6 on substances.
- 7 MR. EDELL: Yes.
- 8 MR. LONG: You are talking about
- 9 differences in cigarettes and you are going into
- 10 did you test all this stuff and this and that, and
- II am saying we may be here a long time, this issue
- 12 will come up again, but to the extent we can
- 13 restrict the discovery here to class certification
- 14 issues, we have a better chance of concluding at
- 15 some reasonable time.
- 16 MR. EDELL: I agree with you. It is
- 17 relevant to the discovery of documents that may or
- 18 may not substantiate his position that there is a
- 19 significant difference with respect to the brands
- 20 that have been manufactured by Lorillard over the
- 21 years. Quite frankly, I don't think for purposes

THE REALTIME REPORTING GROUP, INC.

 ∞

48070

- of class certification there is such a
- 2 differentiation. If they have conducted research
- 3 to see whether or not any of these particular
- 4 brands are more harmful than the regular
- 5 cigarettes, I'm entitled to find that information
- 6 out.
- 7 MR. LONG: At some point. I'll let you
- 8 go ahead. I'm not going to instruct him right
- 9 now. You tend to take the curves to where there
- 10 are more merit issues than class certification. Go
- 11 ahead.
- 12 Q. Research regarding additives?
- 13 A. I mentioned that Dr. Jack Reed is
- 14 director of research.
- Q. Would you receive the results?
- A. We both report to a VP of research.
- 17 Q. Would you get copies of the work that he
- 18 performs testing these various additives?
- 19 A. He doesn't perform it directly. People
- 20 under him do, and generally, I would not get
- 21 copies.

- 1 Q. With respect to the issue of your area
- 2 of expertise, you say that you were an expert in
- 3 the area of blending, correct?
- 4 A. I think I was at one time.
- 5 Q. And blending encompasses what?
- 6 A. Putting together the different types of
- 7 tobacco which results in a pleasing taste when they
- 8 are blended.
- 9 Q. It doesn't involve adding anything at
- 10 that juncture, correct?
- 11 A. Blending, per se, does not.
- 12 Q. No foreign substances?
- 13 A. Not in our terminology, that's not
- 14 blending. That is flavoring.
- 15 Q. Did you conduct any testing to see
- 16 whether or not there were any, there was any
- 17 residual insecticides, pesticides in tobacco or the
- 18 tobacco blends you used?
- 19 A. We do testing on a routine basis or have
- 20 it, we don't do it in-house, but we have some
- 21 conducted.

- 1 Q. Are there any cigarettes that have ever
- 2 been produced by Lorillard that have not been found
- 3 to contain residue of insecticides or pesticides?
- A. Repeat that, please.
- 5 Q. Have there ever been any cigarettes that
- 6 have been manufactured by Lorillard that don't
- 7 contain some residual amount of insecticide or
- 8 pesticide?
- 9 A. This is outside my area of expertise,
- 10 but I doubt it.
- 11 Q. They would all have some residual; is
- 12 that correct?
- 13 A. Yes. Most agricultural products do,
- 14 tomatoes, grapes, anything.
- 15 Q. The answer is yes?
- 16 A. To the best of my knowledge.
- 17 Q. To we are clear, I'm not concerned about
- 18 grapes or any other products, I'm talking about
- 19 cigarettes, all the cigarettes manufactured --
- 20 A. I understand, my knowledge is about as
- 21 great in the others, tomato or tobacco, I am just

```
1 generally aware there are pesticide residues.
```

- Q. It is generally your understanding that
- 3 there is always residual insecticide or pesticide
- 4 found in all of Lorillard's product, correct?
- 5 A. Yes.
- 6 Q. Are any of those residual insect a sides
- 7 or pesticides known or suspected carcinogens?
- 8 MR. LONG: Here we go again. When you
- 9 are talking about carcinogens, are you talking
- 10 about shown to be a carcinogen in animals or
- 11 humans?
- 12 Q. Are there any known carcinogens in
- 13 cigarette smoke that cause cancer in human beings?
- 14 A. I have no idea.
- 15 Q. Beyond your expertise?
- 16 A. I don't know.
- 17 Q. You don't know?
- 18 A. I do not know.
- 19 Q. You never reviewed any research or
- 20 documents at Lorillard that related to the issue of
- 21 any composition of any element in the composition

THE REALTIME REPORTING GROUP, INC.

- 1 of cigarette smoke that caused cancer in human
- 2 beings?
- 3 A. I certainly have read documents that
- 4 related to having identified compounds that were
- 5 considered to be harmful in some manner.
- Q. I'm not talking about harmful in some
- 7 manner, I'm talking about carcinogens.
- 8 A. Specifically, I don't know. I think
- 9 some of the compounds we talked about earlier like
- 10 polynuclear aromatic hydrocarbons are considered to
- 11 be carcinogens. If they are, they certainly appear
- 12 in smoke.
- Q. Are there any carcinogens that we
- 14 discussed earlier today, that are not considered to
- 15 be carcinogens in human beings?
- 16 A. I don't have expertise in this area.
- 17 I'm a chemist, I'm not a toxicologist or whoever
- 18 does this. I used to be a chemist.
- 19 Q. You don't keep up in your area of
- 20 expertise in chemistry; is that correct?
- 21 A. Not diligently, no.

- 1 Q. You would consider yourself to be
- 2 currently an expert in that area?
- 3 A. In chemistry?
- Q. Yes. No, you are not an expert?
- 5 A. No. I am not an expert.
- Q. What is it in cigarette smoke, if you
- 7 know, that contributes to the development of cancer
- 8 in human beings?
- A. This is outside my area of expertise, I
- 10 don't know.
- 11 Q. You don't know whether or not one
- 12 Lorillard cigarette might have that or might not
- 13 have that; is that right?
- 14 A. I don't know that there is a cause and
- 15 effect, I just don't know.
- 16 Q. It is your testimony that you don't
- 17 believe that cigarette smoking causes cancer in
- 18 human beings?
- 19 A. Certainly my testimony that I don't know
- 20 for certainty.
- Q. I'm sorry?

THE REALTIME REPORTING GROUP, INC.

- 1 A. It is my testimony I don't know with
- 2 certainty. I certainly am aware that smokers are
- 3 more likely to contract some diseases than
- 4 nonsmokers, based on epidemiology and other things
- 5 I have read about.
- 6 Q. Is it your understanding that it is more
- 7 likely than not that cigarette smoking causes
- 8 cancer in human beings?
- 9 A. The way I phrased it is my
- 10 understanding, smokers are more likely to have some
- 11 problems than nonsmokers.
- Q. I understand what you are saying. You
- 13 are saying there may be some other thing peculiar
- 14 about smokers?
- 15 A. I'm saying I'm not a medical doctor.
- 16 Q. I'm asking you what your understanding
- is as to whether or not there is anything in
- 18 cigarette smoke that contributes to the development
- 19 of lung cancer in human beings?
- 20 A. I'm telling you I don't know.
- Q. Are you aware as to whether or not there

- 1 is anything in cigarette smoke that contributes to
- 2 the development of heart disease in human beings?
- A. Only from the standpoint of having read
- 4 articles that say nicotine and other components of
- 5 smoke correlate with heart disease, to, again,
- 6 epidemiological studies, that sort of thing,
- 7 associations.
- 8 Q. Is there any difference in any of the
- 9 cigarettes manufactured by Lorillard over all these
- 10 years, insofar as their contributing or causing
- 11 heart disease in smokers?
- 12 A. I don't know that they cause heart
- 13 disease. Our cigarettes have certainly varied over
- 14 the years.
- Q. Do you know what the ingredient is, the
- 16 item is, in the smoke particulate phase or the gas
- 17 phase of cigarette smoke that causes heart disease
- 18 or contributes to heart disease?
- 19 A. I don't know if cigarette smoking causes
- 20 any of these diseases. I can't answer the
- 21 question.

- 1 Q. To you don't know whether or not, more
- 2 likely than not, cigarette smoking contributes to
- 3 the development of heart disease; is that right?
- 4 Not to a one hundred degree certainty?
- 5 A. I think cigarette smokers are more
- 6 likely to have heart problems. The question is
- 7 outside my area of expertise.
- 8 Q. The question is -- if you don't feel
- 9 like you can answer the question, that's another
- 10 issue, Doctor. My question is much more narrow
- 11 than whether or not cigarette smokers may have a
- 12 higher incidence of heart disease. The question is
- 13 whether or not you know -- let me rephrase the
- 14 question.
- 15 Whether or not it is your opinion that
- 16 more likely than not there is something in
- 17 cigarette smoke that contributes to the development
- 18 of heart disease in human beings?
- 19 A. You first asked me if I knew, and then
- you changed the sentence and asked if it were my
- 21 opinion.

THE REALTIME REPORTING GROUP, INC.

- 1 Q. That's my job.
- A. Give me one of the questions.
- 3 (The record was read by the reporter.)
- Q. Dr. Jones, the answer?
- 5 A. My answer is that I don't know, in my
- 6 opinion, but it certainly could be. I think
- 7 cigarette smoking can be a risk factor.
- 8 Q. You don't have an opinion one way on the
- 9 other. Just to we are clear, you have no opinion
- 10 as to whether or not, more likely than not, there
- 11 is something in cigarette smoke that contributes to
- 12 the development of heart disease in human beings
- 13 who smoke cigarettes?
- 14 A. I have certainly read that some of the
- 15 components of cigarette smoke are considered to be
- 16 related to causation of heart disease.
- Q. What are those components?
- 18 A. Carbon monoxide for one.
- 19 Q. We have already established that carbon
- 20 monoxide would be found in any cigarette ever
- 21 manufactured by Lorillard, correct?

- 1 A. Yes.
- Q. What else?
- A. I'm not sure I would assume nicotine.
- 4 Q. I'm sorry?
- 5 A. I have read reports that nicotine is
- 6 associated with an increase in heart disease.
- 7 Q. You are aware that nicotine is dangerous
- 8 to people who have preexisting heart disease,
- 9 correct?
- 10 A. Not particularly, no, I'm not.
- 11 Q. You are not aware that Dr. Spears
- 12 stopped smoking, because his doctor advised him to
- do that, because he had arrhythmias?
- 14 A. I'm aware that he stopped smoking.
- 15 Q. You weren't aware that the reason he
- 16 stopped smoking was because his doctor told him to
- 17 stop smoking because he had arrhythmias, and
- 18 nicotine could be dangerous in people who had
- 19 arrhythmias?
- 20 A. That's not my recollection. He
- 21 occasionally smokes. I remember when he stopped

- 1 smoking.
- Q. You didn't review his deposition
- 3 transcript taken in any matters?
- 4 A. No.
- Q. Have you discussed the issue with him?
- 6 A. His stopping smoking?
- 7 Q. Yes.
- 8 A. Yes.
- 9 Q. He didn't tell you he stopped as a
- 10 result of doctor's orders?
- 11 A. Best of my knowledge, he told me he was
- in the hospital for five days, and he hadn't
- 13 smoked, and it was no problem when he got out, to
- 14 he didn't start smoking again on a regular basis.
- 15 Q. I want to make sure. He didn't tell you
- 16 that the reason he stopped smoking was because his
- 17 doctor advised him to stop smoking?
- 18 A. He never told me that, to my
- 19 recollection. That was 20 years ago.
- Q. Are you aware as to whether or not, in
- 21 fact, nicotine is dangerous for people who have

- 1 arrhythmias?
- A. That is outside my area of expertise.
- Q. Do you have an opinion as to what it is
- 4 in cigarette smoke that contributes to the
- 5 development of obstructive lung disease in human
- 6 beings?
- 7 A. This is an area I don't know anything
- 8 about. I don't know.
- 9 Q. Doctor, you were involved for almost a
- 10 decade in marketing research, correct?
- 11 A. Yes.
- 12 Q. And marketing research means what?
- A. Consumer research and sales analysis,
- 14 would be the two primary functions of the
- 15 department.
- Q. To 1983 to 1992, you were the director
- of marketing research, correct?
- 18 A. Yes, sir.
- 19 Q. What types of studies were being
- 20 performed in the area of marketing research?
- 21 A. Sales analysis, tracking studies, tested

- 1 advertising.
- Q. Focus groups?
- 3 A. Certainly focus groups.
- 4 Q. What else?
- 5 A. That pretty much covers it.
- 6 Investigation of new products, new advertising
- 7 campaigns, a rather large study, a tracking study,
- 8 that gave us information in terms of brand shares
- 9 and demographics. Audits of new brand performance
- 10 and test audit and other sales activities.
- 11 Q. Did you do that to the exclusion of any
- 12 other work for Lorillard? You weren't involved in
- 13 product development, other than in marketing, is
- 14 that correct, during that decade, 1983 to 1992?
- 15 A. I had some involvement.
- 16 Q. What involvement did you have?
- 17 A. Number one, I knew the people, to I
- 18 talked to them about new products, about testing of
- 19 products.
- Q. From a consumer acceptability
- 21 perspective or a safety perspective or both?

- 1 A. Consumer acceptability perspective.
- Q. Were you aware that -- let me back up a
- 3 little bit. What is titration?
- A. I can tell you what it is chemically. I
- 5 am not sure I can tell you what it is, the avenue
- 6 that I think you are taking. It is used in
- 7 sentences with titration and compensation. I'm not
- 8 sure I can define it in that sense.
- 9 Q. You never saw the word used in Lorillard
- 10 documents or heard your colleagues talking about
- 11 titration with respect to products manufactured and
- 12 sold by Lorillard?
- 13 A. I don't believe I have.
- 14 Q. There were no discussions or you never
- 15 saw any documents that related to the fact that
- 16 people who were smoking lower tar and nicotine
- 17 cigarettes, in fact, smoke more cigarettes?
- 18 A. I don't believe that to be the case. I
- 19 think that gets to what I call compensation. I
- 20 don't think that differs significantly from other
- 21 smokers to other smokers.

- 1 Q. Let me back up a little bit. You did
- 2 either discuss that issue or see documents that
- 3 related to that issue in your capacity as an
- 4 employee of Lorillard?
- 5 A. When I was director of marketing
- 6 research, we did our big surveys, we asked people
- 7 how many cigarettes they smoked per day. To my
- 8 conclusion was based on that. It was not a
- 9 significant difference in the claimed smoking per
- 10 day among the ultra-light smokers versus the
- 11 full-flavored smokers, perhaps one or two
- 12 cigarettes per day.
- 13 Q. To I understand it, the results of your
- 14 study reflected the fact that they did smoke more
- 15 cigarettes.
- 16 MR. LONG: I object. That's a
- 17 mischaracterization of what he said.
- Q. Did they, didn't they, whether it be
- one, two, three, four, ten, did the people smoking
- lower tar and nicotine cigarettes consume more
- 21 cigarettes than those smoking the higher tar and

- nicotine cigarettes?
- 2 A. I believe I said we didn't see a
- 3 significant difference, but they claimed it might
- 4 have been as much as two cigarettes a day, probably
- 5 less.
- 6 Q. Who claimed?
- 7 A. The smoker on questioning.
- 8 O. To the smokers were telling you they
- 9 were smoking more; is that right?
- 10 A. The smokers were answering the question
- 11 how many cigarettes do you smoke a day.
- 12 Q. And the people smoking the lower tar and
- 13 nicotine cigarettes were saying they were smoking
- 14 more cigarettes?
- 15 A. I don't think it was significantly
- 16 different, but I remember the number, it was about
- 17 one cigarette more per day.
- 18 Q. Did you make any determination as to
- 19 whether or not there was a difference in the way
- 20 they were smoking cigarettes?
- 21 A. No.

- Q. Whether they breathed in more deeply
- 2 than people who were smoking higher tar and
- 3 nicotine cigarettes?
- 4 A. No.
- 5 Q. You never explored that issue?
- 6 A. No. I'm aware of the issue, because of
- 7 the recent things in perhaps changing the
- 8 methodology on the smoking machines. We never
- 9 studied the issues with consumers, to my knowledge.
- 10 Q. Did you ever note that there was a
- 11 difference in the way in the low tar and nicotine
- 12 smokers smoked versus higher tar and nicotine
- 13 smokers?
- 14 A. It is my personal belief that they don't
- 15 differ.
- 16 Q. They smoke the same?
- 17 A. It is my personal belief.
- Q. Do you have a professional belief?
- 19 A. I have never done a quantitative study.
- 20 I am basing this on observation and experience.
- Q. To as far as you know, or as far as you

- 1 are concerned, there is no difference; is that
- 2 correct?
- A. That's correct in general. I am
- 4 certainly aware of reports that some people cover
- 5 the holes. I think that is a tiny, tiny fraction
- 6 of low-tar smokers.
- 7 Q. When you say "people cover the holes"
- 8 you are talking about people who are covering the
- 9 holes in the cigarette paper or filter?
- 10 A. The filter, yes.
- 11 Q. In order to get more smoke?
- 12 A. Yes.
- 0. Is that correct?
- 14 A. Yes.
- 15 Q. That was an alleged problem with the
- smoking machines that were being used by the FTC,
- 17 correct?
- 18 A. I don't think to, I think it was an
- 19 alleged problem with one particular brand at one
- 20 time.
- Q. I thought there was an issue as to

- 1 whether or not the machines used by the FTC
- 2 simulated the way people really smoked.
- A. I don't think they are intended to
- 4 simulate the way people really smoke. People smoke
- 5 in a variety of ways. The machines are meant to be
- 6 a standard.
- 7 Q. Did you ever see any studies that
- 8 suggested that the individual smokers smoked in
- 9 order to achieve a certain level of nicotine
- 10 intake?
- 11 A. I don't believe I have ever seen a study
- 12 in that regard. I have been around, I have heard
- 13 discussions in that area.
- Q. When you say "discussions" within
- 15 Lorillard?
- 16 A. Yes.
- Q. What was your understanding of those
- 18 discussions?
- 19 A. Some people were of the opinion that
- 20 people smoked to obtain a certain level of
- 21 nicotine, with which they were comfortable, and

- 1 that was related to how much they smoked per day.
- Q. Were any studies ever conducted by
- 3 Lorillard in that regard?
- 4 A. Not to my knowledge.
- 5 Q. Marketing didn't do any research in that
- 6 regard?
- 7 A. No.
- 8 Q. Were there any type of marketing
- 9 research that was specifically avoided by
- 10 Lorillard?
- 11 A. Yes.
- 12 Q. What type of marketing research was at
- 13 Lorillard, other than selling to minors?
- A. Selling to minors was the first thing.
- 15 We didn't talk to minors.
- 16 Q. I would qualify that other than selling
- 17 to minors?
- 18 A. Or talking to minors.
- 19 Q. Or talking to minors?
- 20 A. It was also our policy not to interview
- 21 nonsmokers on the subject of smoking I think the

THE REALTIME REPORTING GROUP, INC.

- 2 talk to underage people, whether or not they
- 3 smoked.
- 4 Q. And when you say "minors," talking about
- 5 people younger than 21?
- 6 A. Talking about younger than 18 at that
- 7 time.
- Q. Any other type of marketing research
- 9 that was specifically avoided by Lorillard?
- 10 MR. LONG: I object, vague and
- 11 ambiguous.
- MR. EDELL: You can answer.
- MR. LONG: If can you understand it.
- 14 A. None that I am aware of. If you want to
- ask me some for examples, I will try to answer.
- 16 Q. I don't know all the marketing research
- 17 that was done, to I don't know how to ask that
- 18 question any more specifically, Doctor, you were
- 19 there for 25 years.
- 20 A. I was there for eight and a half in
- 21 marketing research.

- 1 Q. Marketing research you were there from
- 2 1982 to 1993?
- A. I think it was more like '83 to '92,
- 4 eight years.
- 5 Q. Eight and a half years. During those
- 6 eight and a half years you were in charge of
- 7 marketing research, was there any other marketing
- 8 research avoided by Lorillard, other than that
- 9 which you have already described?
- 10 A. I don't recall having avoided anything.
- 11 We got requests from different groups to study
- 12 things. We usually did it.
- Q. Doctor, was it your area of expertise
- 14 to --
- 15 A. I need to go back and answer further
- 16 that last question. We generally, I just thought
- 17 of it, did not ask questions concerning smoking and
- 18 health.
- 19 Q. Why?
- 20 A. When we were surveying people.
- 21 Q. Why?

- A. I don't know. I know we did not do it.
- Q. Where did you get those instructions?
- A. I just remember it, that we didn't do
- 4 it. I'm not sure that anybody specifically asked
- 5 for it. I just remember conversations, when I took
- 6 over the department, that that was an area we never
- 7 studied and had no interest in.
- 8 Q. You didn't want to know what smokers
- 9 knew or didn't know about the health hazards of
- 10 smoking, is that it?
- 11 A. I just tried to completely answer the
- 12 question, and the thought came to me.
- 13 Q. Now I'm asking you a guestion about the
- 14 statement.
- 15 A. I told you we didn't do it when we came
- 16 there, we didn't do it under my reign and I was
- 17 never asked to do it.
- 18 Q. I'm asking you: While you were director
- 19 of marketing at Lorillard, did you have any
- 20 interest in making a determination as to what
- 21 people knew or understood about the potential

- 1 health hazards of smoking?
- 2 A. I am sure I had some interest. We
- 3 didn't study it. There would be unelicited
- 4 responses in focus groups probably.
- 5 Q. Was that an issue of interest to
- 6 Lorillard?
- 7 A. I don't think to.
- 8 Q. It wasn't an interest at Lorillard to
- 9 make a determination as to what the consumers knew
- 10 or didn't know about the potential health hazards
- of their product; that is your statement?
- 12 A. Not to my knowledge. I remember one
- 13 question that was asked in tracking studies that
- 14 tangentially relates to that, and it was a
- 15 question, we would ask people if you could have
- 16 your choice of one or two things, would you prefer
- 17 to have your cigarette reduced in tar and nicotine
- 18 or would you prefer to have it reduced in price.
- 19 Q. The answer was price?
- 20 A. Generally.
- Q. Doctor, do you have any expertise with

1 respect to the literature regarding the physiology

- 2 and psychology of smoking?
- 3 A. I once did a literature review. I would
- 4 say I don't have expertise 15 or 18 years ago, I
- 5 did a review of literature.
- 6 Q. In 1979, 1980, you did that review?
- 7 A. I think that's about right.
- 8 Q. Did you bring that review with you?
- 9 A. No, sir.
- 10 Q. Why?
- 11 A. I didn't know it is relevant. It is not
- 12 mentioned, anything like that in my affidavit, to
- 13 my knowledge.
- 14 Q. What were the results of your review?
- 15 A. There were no results. It was a review
- 16 generally of what was in the literature.
- 17 Q. When we were talking about the
- 18 physiological effects of smoking, we are talking
- 19 about what?
- 20 A. Basically, I think the effects of
- 21 nicotine, based on that paper.

Q. So in 1979, 1980, you surveyed the world

- 2 literature on the effects of nicotine on smokers?
- A. I don't know how wide ranging it was. I
- 4 suppose I did. The library did the search for me,
- 5 I remember articles from England, to I guess it is
- 6 fair to say I reviewed the world literature.
- 7 Q. Why did they ask you to do it, if you
- 8 had no expertise?
- 9 A. I'm not sure. It may have been
- 10 something I was interested in at the time and
- 11 decided to do it on my own. I'm not sure I was
- 12 asked to do it. I don't really remember.
- 13 Q. Who is Richard E. Smith?
- 14 A. He was a group brand director at one
- 15 time and then became, I think his title was
- 16 vice-president marketing/development.
- 17 Q. 1980, do you know what his position was?
- 18 A. Either a group brand director or had
- 19 been made vice-president at that time.
- Q. You don't recall that you were given the
- 21 specific assignment to conduct that research, as

- 1 opposed to your having some interest in it, and
- 2 deciding to --
- A. I don't recall. It wouldn't have been
- 4 unlikely for him to ask me to take a look at it.
- Q. Why would he ask you?
- 6 A. I was one of the few people he knew and
- 7 worked with on a regular basis.
- 8 Q. This was in conjunction with a five-year
- 9 plan for Lorillard, they were relying upon you to
- 10 conduct this research, correct?
- 11 A. I honestly don't remember if it relates
- 12 to the five-year plan. It is not mentioned in this
- one you handed to me. I don't know.
- Q. Would you be surprised to learn that
- 15 they were relying upon you to conduct this research
- 16 with respect to the five-year plan for Lorillard?
- MR. LONG: Object to the form of the
- 18 question.
- MR. EDELL: Why? What is wrong with
- 20 it?
- MR. LONG: Would you be surprised?

THE REALTIME REPORTING GROUP, INC.

```
1 MR. EDELL: Yes. Would you be
```

- 2 surprised? Do we have an answer to that question?
- 3 A. You are waiting for me?
- 4 Q. Yes.
- 5 A. No. I would not be surprised, but it
- 6 certainly wouldn't have a lot to do with the
- 7 five-year plan.
- 8 Q. Sorry?
- 9 A. That review paper wouldn't have much to
- 10 do with our future marketing efforts for the
- 11 five-year plan. It wouldn't have been a key part
- 12 of it. If it were, I would have a better memory of
- 13 it.
- 14 Q. You were part of the group that was
- 15 putting together materials for five-year plan,
- 16 weren't you?
- 17 A. Yes.
- Q. Did you have any other assignment with
- 19 respect to the five-year plan other than
- 20 summarizing relevant information on physiology and
- 21 psychology of smoking?

THE REALTIME REPORTING GROUP, INC.

! 105

```
1 MR. LONG: I object to the form of the
```

- 2 question. He testified he can't recall whether
- 3 that was an assignment in the five-year plan or
- 4 not.
- 5 Q. Let me rephrase it then.
- 6 Do you recall whether or not you had any
- 7 responsibility other than summarizing the world
- 8 literature with respect to the physiology and
- 9 psychology of smoking?
- 10 A. I'm sure that I did.
- 11 Q. What was the other area of
- 12 responsibility?
- MR. LONG: I object again. You keep
- 14 saying, he testified that he didn't know whether
- 15 that was part of five-year plan. You heard the
- 16 testimony. You keep saying other than that
- 17 responsibility did you have others? He hasn't
- 18 testified that was his responsibility under the
- 19 five-year plan, to your question assumes facts not
- 20 in evidence. I want to get the objection on the
- 21 record.

- 1 MR. EDELL: To there is an objection to
- 2 the form of the question. Is that it?
- MR. LONG: It is a misleading question,
- 4 yes, assumes facts not in evidence.
- 5 MR. EDELL: Let's mark this for
- 6 identification -- what number are we up to?
- 7 (Whereupon, Plaintiff's Exhibit No.
- 8 88, literature review memo, marked.)
- 9 Q. I will show you Plaintiff's Exhibit 88,
- 10 which has not been stamped as confidential by
- 11 Lorillard.
- 12 Can you identify for us what P-88 is?
- 13 A. This is the memo you are referring to in
- 14 which I reviewed the literature on the behavior and
- 15 pharmacological factors in smoking in 1980.
- 16 Q. You prepared that?
- 17 A. Yes.
- 18 Q. Does that refresh your recollection as
- 19 to whether or not that had anything to do with the
- 20 five-year plan?
- 21 A. Yes. According to the cover letter,

- that is exactly why it was done.
- Q. It does refresh your recollection that
- 3 it was in conjunction?
- A. Not particularly, because it was never a
- 5 big deal or particularly actionable.
- 6 Q. How many pages is that document?
- 7 A. Maybe 15, 18. 16 plus the cover.
- 8 Q. May I see it, please? You did prepare
- 9 this document; is that correct?
- 10 A. Yes, sir.
- 11 Q. That is your --
- 12 A. Yes, sir.
- Q. Are those your initials on the first
- 14 page?
- 15 A. Yes, sir.
- 16 Q. Who are the people to whom you are
- 17 sending this?
- 18 A. They were the people that were on the
- 19 five-year planning committee.
- Q. And why is it, why is there typed across
- 21 the top here "confidential"?

THE REALTIME REPORTING GROUP, INC.

- 1 A. Five-year plan, we are working on what
- 2 we call a five-year marketing plan, to all of that
- 3 would be confidential.
- Q. You recall writing in 1990 that
- 5 undoubtedly nicotine serves as the primary role in
- 6 cigarette smoking?
- 7 MR. LONG: You want to let him have a
- 8 copy of the document when you are reading from it,
- 9 to we can check it?
- MR. EDELL: Take a look at that.
- 11 A. I don't have a specific recollection of
- 12 having said that, but if it is typed here, I'm sure
- 13 I did.
- 14 O. You have no reason to believe that that
- 15 isn't the case?
- MR. LONG: I object. There is a
- 17 difference between what he believes and what he
- 18 wrote. It is a literature review. If you want to
- 19 ask him about his literature review, that is one
- 20 thing. You are assuming that everything he writes
- 21 in there is his opinion, rather what it is, which

THE REALTIME REPORTING GROUP, INC.

- 1 is a literature review.
- Q. You used the word "undoubtedly", didn't
- 3 you?
- 4 A. Yes. Followed by a reference to
- 5 somebody named Nelson that reports that nicotine
- 6 has been described as a psychoactive agent.
- 7 Q. After undoubtedly, what does it say?
- 8 A. Undoubtedly, nicotine serves a primary
- 9 role in cigarette smoking.
- 10 Q. There is a citation after that?
- 11 A. No. The beginning of the next sentence
- 12 there is.
- Q. To whose words are they, that you just
- 14 read into the record?
- 15 A. They could have been my personal opinion
- or my opinion based on having read all that
- 17 literature that was a conclusion from the
- 18 literature. Could have been either one.
- 19 Q. You have no idea why they asked to you
- 20 do this, is that correct? You have no idea what
- 21 this related to in the context of the five-year

- 1 plan?
- A. I'm not certain that it was not my idea
- 3 to do this.
- Q. I'm asking you what you recall?
- 5 A. It may have been my area of interest
- 6 that I decided to do it, as opposed to having it
- 7 requested. I just don't know, I don't recall.
- 8 There was a time in my career, when I had extra
- 9 time on my hands.
- 10 Q. To it is your recollection that you may
- ll have just been sitting around doing nothing and you
- 12 said I'm going to do research on the physiology and
- 13 the psychology of smoking?
- 14 A. Not precisely, I rarely would say I am
- 15 sitting around doing nothing.
- Q. I'm light, guys, I have some time, why
- 17 don't I do some research on the physiology and
- 18 psychology of smoking?
- 19 A. Had I decided to do it, I wouldn't have
- 20 had to tell them, I would have just done it, if I
- 21 thought it was worthwhile.

```
1 Q. You don't know as you sit here and
```

- 2 review that, whether or not that was just an
- 3 academic exercise that you were doing in your spare
- 4 time or whether or not that was something that was
- 5 integrally related with the five-year plan?
- A. I certainly thought it would be of
- 7 interest to the people working on the five-year
- 8 plan.
- 9 Q. Why?
- 10 A. Because it related to smoking.
- 11 Q. It related to why people smoked and kept
- 12 smoking?
- 13 A. I suspect there are references in that
- 14 regard in here, he talks about behavioral factors.
- 15 Q. Isn't that the real issue that is being
- 16 addressed in that paper?
- 17 A. Why people smoke?
- 18 Q. And why they keep smoking.
- 19 A. It is certainly one of the issues
- 20 addressed in the paper.
- Q. And why was that important to the

- 1 five-year plan?
- A. I am not sure that that particular
- 3 element was.
- Q. What else is discussed in that paper as
- 5 to, other than why people smoke and why people
- 6 continue to smoke?
- A. If I recall, there were statements in
- 8 there that smokers, either smokers or nicotine had
- 9 better motor skills and attention spans and it
- 10 wasn't just as narrow as you proposed. Nicotine is
- 11 an important part of cigarettes, to it was
- 12 certainly important in 1979 to review it.
- Q. Why was it an important part of
- 14 cigarettes?
- A. Why is nicotine an important part?
- 16 Q. Yes.
- A. Based upon this, because of its, to some
- 18 degree, its psychopharmacological factors or
- 19 effects, I guess one would say.
- Q. Was there any other agent, other than
- 21 nicotine, that was found to have a profound effect

THE REALTIME REPORTING GROUP, INC.

- 1 upon why people smoke and continue to smoke, other
- 2 than nicotine?
- 3 MR. LONG: You mean in this paper?
- 4 MR. EDELL: That he has ever become
- 5 aware of. Make it broad and we can narrow it
- 6 down.
- 7 A. I think nicotine is one of the important
- 8 factors in smoking. I stated that earlier.
- 9 Q. Is it fair to say it is the most
- 10 important factor from a pharmacological
- 11 perspective?
- 12 A. Pharmacology is outside my area of
- 13 expertise.
- 14 Q. That's why you were asked --
- A. But my personal belief is probably
- 16 that's the case.
- 17 Q. Isn't that your understanding from
- 18 reviewing the world literature on the issue in
- 19 1980?
- 20 A. I don't remember everything I learned
- 21 from this in 1980.

THE REALTIME REPORTING GROUP, INC.

```
1 Q. Take your time and look at it?
```

- A. I'm not sure I can read it all. It is a
- 3 poor copy.
- Q. If there is summary you can't read, I'm
- 5 sure we can get a copy from your counsel. We can
- 6 get it faxed from you, I'm sure you guys in the
- 7 spirit of cooperation want to provide the entire
- 8 document?
- 9 A. Restate the question, if you would.
- 10 Q. Is it fair to say that it is the most
- 11 important factor from a pharmacological
- 12 perspective, that is nicotine, regarding the issue
- of why people smoke and continue to smoke?
- MR. LONG: And I said, you mean in the
- 15 paper?
- 16 MR. EDELL: Based upon his understanding
- 17 of the world literature, either in the context of
- 18 this paper or from any other understanding.
- 19 MR. LONG: To it is not limited to
- 20 what's in this paper?
- 21 MR. EDELL: That's correct.

- 1 MR. LONG: No reason for him to be
- 2 looking at the paper then?
- 3 MR. EDELL: Certainly is. It
- 4 encompasses the paper.
- 5 MR. LONG: Objection.
- 6 MR. EDELL: You can answer.
- 7 A. The paper talks about areas other than
- 8 nicotine.
- 9 Q. That wasn't my question as to what the
- 10 paper referenced.
- 11 MR. LONG: That's the problem with your
- 12 question
- MR EDELL: There is a specific question.
- MR. LONG: What was the question?
- 15 Q. You said that nicotine was an important
- 16 factor in people smoking, correct?
- 17 A. That's my personal belief.
- 18 Q. I'm asking you whether or not, in fact,
- 19 it is not from a pharmacological perspective the
- 20 primary factor?
- 21 A. I don't have expertise. I wouldn't be

THE REALTIME REPORTING GROUP, INC.

82

1 surprised if it does. It is outside my area of

- 2 expertise.
- Q. Did your paper come to any conclusions
- 4 in that regard?
- 5 A. It came to a lot of conclusions, not all
- of which related to nicotine.
- 7 Q. I know that. That is why I said: Did
- 8 you come to that conclusion -- did your paper come
- 9 to that conclusion in any regard?
- 10 A. I would think it has to, from the
- 11 paragraph you referenced earlier, undoubtedly
- 12 nicotine serves a primary role in cigarette
- 13 smoking.
- Q. Do you have any reason to disbelieve
- 15 that that is the fact?
- 16 A. No. I have no reason to disbelieve
- 17 that.
- Q. Do you have any reason to change your
- 19 opinion as expressed in 1980 on that issue?
- 20 A. No. Again, we said I'm not sure if that
- 21 was my opinion or what the literature said.

THE REALTIME REPORTING GROUP, INC.

- 1 Q. Based upon your review of that, you
- 2 don't know whether or not that is your opinion
- 3 based upon the world literature?
- 4 MR. LONG: I object to this same
- 5 question was asked five minutes ago.
- 6 MR. EDELL: Maybe it will refresh his
- 7 recollection, now that he has reviewed more of the
- 8 document.
- 9 MR. LONG: Give me a break.
- 10 A. I agree that nicotine serves a primary
- 11 role in cigarette smoking as stated here. That is
- 12 also my personal belief.
- Q. Thank you. Did you ever publish the
- 14 information contained in this paper?
- 15 A. No, sir.
- 16 Q. Did you ever convey the conclusions in
- 17 this paper to your consumers, Lorillard's
- 18 consumers?
- 19 A. No.
- 20 Q. Did this paper relate in any way to the
- 21 fact that there is literature that suggested in

THE REALTIME REPORTING GROUP, INC.

- 1 1980, that nicotine causes a physiological
- 2 dependence in the people who use cigarettes?
- 3 MR. LONG: Repeat that.
- 4 MR. EDELL: Did this paper relate in any
- 5 way to the fact that there is literature that
- 6 suggested in 1980 that nicotine causes a
- 7 physiological dependence in the people who use
- 8 cigarettes?
- 9 MR. LONG: Object to the form of the
- 10 question. It is nonsensical. He has already
- 11 testified that this is a review of published
- 12 information. I mean that's what he has testified
- 13 to. In that context, I don't think your question
- 14 makes any sense.
- 15 MR. EDELL: Okay. He can still answer
- 16 it. Won't be the first time.
- MR. LONG: First time what?
- MR. EDELL: I asked a nonsensical
- 19 question.
- MR. LONG: First time I have said to
- 21 today.

```
1 MR. EDELL: Not intentionally.
```

- 2 MR. LONG: Of course.
- MR. EDELL: Doctor?
- A. If I understood the question, you are
- 5 asking me if this paper and the findings in this
- 6 paper related to the statement you made about
- 7 nicotine around 1980?
- 8 Q. Yes.
- 9 A. To my knowledge, no. This was not
- 10 widely distributed.
- 11 Q. Not widely distributed?
- 12 A. Not in R and D. Most of these people
- 13 were in marketing.
- 14 Q. Let me see if I can rephrase the
- 15 question. Did this paper relate in any way to the
- 16 fact that there was literature in 1980 that
- 17 suggested that people who smoked cigarettes became
- 18 physiologically dependent upon the cigarettes?
- 19 A. Counselor, I'm sure there were papers
- 20 well before 1980, in which people claimed that. I
- 21 may well have referenced some in this document.

THE REALTIME REPORTING GROUP, INC.

1 Q. Okay. Did you have any reason from a

- 2 professional perspective to disagree with that
- 3 conclusion?
- 4 A. To the conclusion that nicotine and
- 5 cigarettes does what?
- 6 Q. Causes some physiological dependence in
- 7 people who smoke?
- 8 A. I think cigarettes are habit forming and
- 9 nicotine contributes to that. To in that sense,
- 10 yes.
- 11 Q. That wasn't my question.
- 12 A. You used the word "dependence"?
- 13 Q. Physiologically.
- 14 A. That is outside my area of expertise.
- 15 Q. All right. You were the one who did
- 16 this review with respect to the physiology of
- 17 cigarettes, correct?
- 18 A. Yes.
- 19 Q. Insofar as it pertains to smokers,
- 20 right?
- 21 A. Yes.

Q. As well as the psychology of smoking

- 2 insofar as it pertains to smokers, correct?
- A. As limited by these sources, yes.
- 4 Q. You didn't have the expertise to do this
- 5 research; is that correct?
- A. I certainly had the expertise to do the
- 7 literature review, not to do the research that is
- 8 reported in the paper, no.
- 9 Q. You had the expertise to interpret it,
- 10 did you not?
- 11 A. I felt that I did, obviously.
- 12 Q. To did the people with whom you were
- working, did they not?
- 14 A. I think very little in this paper were
- 15 my interpretations, I think the bulk of this paper
- 16 said what was said in the literature. It was a
- 17 condensation of various articles on the topics.
- 18 Q. Do you know whether or not any of your
- 19 conclusions were used in the creation of the
- 20 five-year plan?
- MR. LONG: Object to the form of the

THE REALTIME REPORTING GROUP, INC.

2480754

- 1 question. You are saying his conclusions. He has
- 2 already said he doesn't know that this simply
- 3 doesn't state the conclusions of others.
- 4 MR. EDELL: You can answer the
- 5 question.
- A. I don't think anything related to this
- 7 appeared in the five-year plan.
- 8 Q. Did any research that was conducted by
- 9 Lorillard regarding how people viewed the potential
- 10 health hazards of a particular brand relate to the
- 11 five-year plan?
- 12 A. Restate that, please.
- Q. Did any research conducted by Lorillard
- 14 review how people viewed the potential health
- 15 hazards of a particular brand relate to the
- 16 five-year plan?
- MR. LONG: Which five-year plan?
- MR. EDELL: The one that you are talking
- 19 about, the one you did the literature search for?
- 20 A. I think I stated earlier, I don't recall
- 21 ever doing research in that area.

THE REALTIME REPORTING GROUP, INC.

- 1 Q. To the answer is?
- 2 A. The answer is we didn't conduct that
- 3 type of research.
- Q. Did you have others conduct it for you?
- 5 A. I don't know of any research in that
- 6 vein being conducted.
- 7 When I say "we didn't conduct it" that
- 8 would extend to our suppliers.
- 9 Q. It would extend to the people with whom
- 10 you consulted on the five-year marketing plan?
- 11 A. Yes, but not one of these persons at the
- 12 time was director of marketing and research. The
- other people were not in the research area and
- 14 marketing.
- 15 MR. EDELL: Let's take a break for
- 16 lunch.
- 17 (Discussion off the record.) (Lunch.)
- 18 Q. Dr. Jones, how would you define a light
- 19 smoker?
- 20 MR. LONG: You mean a light smoker of
- 21 cigarettes or a smoker of light cigarettes?

- 1 MR. EDELL: A light smoker of
- 2 cigarettes.
- A. Fewer than ten cigarettes per day would
- 4 be my personal opinion.
- 5 O. How much?
- 6 A. Fewer than ten cigarettes per day.
- Q. If there a definition you use from a
- 8 marketing perspective?
- 9 A. That was the definition we used for
- 10 marketing.
- 11 Q. I wanted to see if there was something
- 12 as opposed to your professional experience. Let's
- 13 keep these on the same track. I'm not asking
- 14 necessarily for your personal opinion, but your
- opinion here as an expert and as someone who worked
- 16 for 20 something years, 30 years, 20 something
- 17 years, how many years, 30 years?
- 18 A. Just over 28.
- MR. LONG: That's if you have a
- 20 professional view.
- MR. EDELL: That's correct.

THE REALTIME REPORTING GROUP, INC.

- 1 Q. How would you characterize a moderate
- 2 smoker?
- 3 A. Between ten and twenty cigarettes per
- 4 day.
- 5 Q. And how would you characterize a heavy
- 6 smoker?
- 7 A. A pack and a half, two packs a day or
- 8 more.
- 9 Q. Why is it that people, from a marketing
- 10 perspective, you keep people in those three
- 11 categories?
- 12 A. I'm not sure we did from a marketing
- 13 perspective. We did not as a rule interview
- 14 smokers who claimed to smoke fewer than ten
- 15 cigarettes per day.
- 16 Q. Why?
- 17 A. We just didn't think they would be
- 18 representative of the smoking population with their
- 19 answers.
- Q. What would your definition as someone
- 21 who is representative of the smoking population be?

THE REALTIME REPORTING GROUP, INC.

- A. Someone who claimed to smoke more than
- 2 ten cigarettes per day.
- Q. Any particular length of time, more than
- 4 a year, five months, more than ten months?
- 5 A. I don't recall ever asking those
- 6 particular questions.
- 7 Q. To from a definitional perspective, it
- 8 didn't make a difference how long they were smoking
- 9 ten cigarettes or more a day to be representative
- 10 of the smoking population?
- 11 A. No, sir.
- 12 Q. Before I forget, have any documents,
- 13 have you brought with you any documents that are
- 14 not subject to a confidential stamp?
- MR. LONG: Yes.
- MR. EDELL: May we see those documents?
- MR. LONG: Sure.
- 18 MR. EDELL: Would you be adverse to our
- 19 marking the documents that are confidential, to
- 20 that we have some way of --
- MR. LONG: We only have one document

THE REALTIME REPORTING GROUP, INC.

- 1 that is marked confidential and there were some
- 2 numbers on there that we have taken off.
- 3 MR. GUSTAFSON: There is more than one.
- 4 MR. LONG: It tells you what he looked
- 5 at and he can tell you why he looked at it.
- 6 Q. Doctor, who drafted the affidavit that
- 7 you signed in this matter?
- 8 A. A draft was done by my attorneys.
- 9 Q. Who were your attorneys?
- 10 A. The gentlemen in this room.
- 11 Q. All of these gentlemen in this room?
- 12 A. Gary and Craig and James.
- Q. Did it go through different drafts?
- 14 A. I believe there were two.
- Q. Did you make any changes in the first
- 16 draft?
- 17 A. Yes, sir.
- 18 Q. What changes were they? Here is
- 19 Plaintiff's Exhibit 15 that is the affidavit that
- 20 we were supplied.
- 21 A. I think did we not also supply the

- 1 draft?
- MR. LONG: Yes.
- THE WITNESS: There are only a couple of
- 4 places I need to refer to it to save us time.
- Page two, top paragraph, which is a
- 6 continuation of paragraph two.
- 7 O. Yes.
- 8 A. Next to the last sentence" is a
- 9 substantially different product than. " I have
- 10 changed that to "from", and also in the last
- 11 sentence, changed the word "than" to "from" in the
- 12 final one.
- Page three, paragraph six, capitalized
- 14 nicotine in the two instances, the third sentence
- 15 from the bottom of paragraph six, and page four,
- 16 section on reconstituted tobacco at the top of the
- 17 page, took out one sentence which appears in this
- 18 first draft.
- 19 Q. What is that sentence?
- 20 A. That sentence read: "Plaintiffs claim
- 21 that one of the methods used to manipulate in

- 1 quotes nicotine levels in cigarettes is through the
- 2 use of reconstituted tobacco."
- 3 Q. You took that out? Question mark.
- 4 A. I assume I did, because it is not in my
- 5 final one. I may have discussed it with my
- 6 attorneys.
- 7 Q. How was the affidavit prepared? Did
- 8 they meet with you first?
- 9 A. Yes.
- 10 Q. Did they interview you?
- 11 A. Yes, sir.
- 12 Q. Regarding just the issues that are
- 13 contained in this document?
- 14 A. I think that was the case. These were
- 15 the topics we covered.
- 16 Q. Then they drafted the affidavit, you
- 17 made these changes that you just described and you
- 18 signed it, correct?
- 19 A. Yes, sir.
- Q. What was your understanding as to why
- 21 you were asked to prepare this affidavit? Or to

- 1 sign this affidavit?
- A. That there was a case, and these were
- 3 questions based upon my position in the company,
- 4 that I was the logical one to generate a response
- 5 to.
- 6 Q. You came to the conclusion that you were
- 7 the logical person?
- 8 A. They did.
- 9 Q. They did?
- 10 A. Yes.
- 11 Q. Is there anyone at the company who knows
- 12 more about the composition of the cigarettes
- 13 manufactured over these many years by Lorillard
- 14 other than you?
- MR. LONG: You mean knows more than
- 16 him?
- 17 Q. More than you. I'm sorry. Does anyone
- 18 at Lorillard know more about the composition of the
- 19 cigarettes manufactured and sold by Lorillard over
- 20 these many years than you do?
- 21 A. Yes. I would think to, people that have

THE REALTIME REPORTING GROUP, INC.

- Q. Can you give us the names of those
- 3 individuals?
- 4 A. Off the top of my head, referring to the
- 5 things I discussed in the affidavit, the technical
- 6 parts of it.
- 7 Q. Referring to the composition of
- 8 cigarettes manufactured by Lorillard over these
- 9 many years?
- 10 A. Dr. Spears would certainly have a longer
- 11 history than me. He predated me by ten years or
- 12 to.
- Q. Anyone else?
- 14 A. There are people in manufacturing that
- 15 have been there longer, but they wouldn't have the
- 16 understanding of the things I have addressed. They
- 17 would certainly know more about manufacturing, per
- 18 se.
- 19 Q. Talking about the composition of the
- 20 cigarettes?
- 21 A. The compositioning includes blends and

- 1 things like that, to I mean they would have some
- 2 awareness, but not in detail.
- 3 Q. I'm looking for the individuals you
- 4 believe may have more knowledge than you concerning
- 5 the composition of the cigarettes manufactured by
- 6 Lorillard?
- 7 A. I would say it would be Dr. Spears and
- 8 Dr. Vellow Norman, who have longer tenures in the
- 9 industry than I have, and both have a technical
- 10 background.
- 11 Q. Do you know why they were not chosen to
- 12 act as experts in this case?
- 13 A. No. I do not know.
- 14 Q. You don't know whether or not it was
- 15 because they had more exposure from a
- 16 cross-examination perspective?
- 17 MR. LONG: Object. He answered your
- 18 question. Here you go trying to refresh the
- 19 recollection by rephrasing the question.
- MR. EDELL: Well, it works.
- MR. LONG: Not any more.

THE REALTIME REPORTING GROUP, INC.

Q. Let's take a look at your evidence. Do

- 2 you have it in front of you? P-15. Here is the
- 3 original document, at least the original exhibit.
- 4 Let's take a look at the second
- 5 paragraph. You didn't have personal knowledge of
- 6 this example that you used in paragraph two, did
- 7 you? You weren't even with the company during that
- 8 time period?
- 9 A. I had knowledge.
- 10 Q. From the documents you reviewed?
- 11 A. Yes, from just being associated with the
- 12 company for a long time, I know the history of some
- of the brands, some of the history of some of the
- 14 brands.
- 15 Q. How did you know those, how did you
- 16 learn that information?
- 17 A. Both from documents and from
- 18 conversations with people in the company over time.
- 19 Q. Who, who?
- 20 A. Primarily to be responsive to paragraph
- 21 two, it would be other chemists in product

THE REALTIME REPORTING GROUP, INC.

- development.
- Q. Who are they?
- A. You want names of people?
- 4 Q. Exactly.
- 5 A. People that were around in product
- 6 development, in 1965, if we take that date, two
- 7 people that come to mind were a gentleman named
- 8 John Maghetti.
- 9 Q. Where is he today?
- 10 A. Retired.
- 11 Q. Where?
- 12 A. Greensboro, as far as I know. Howard
- 13 Smith.
- 14 Q. Where is he?
- 15 A. He is retired, and lives in Greensboro,
- 16 and Charlie Tucker, retired, Greensboro.
- 17 Q. Take a look at paragraph three. Where
- 18 did you gain this information?
- 19 A. Which specific part are you referring
- 20 to?
- Q. The goal of Lorillard cigarette design

- 2 the time period that you weren't involved in
- 3 product development?
- 4 A. It is a basic understanding, I mean,
- 5 anyone that is trying to produce a product wants
- 6 the consumers to like it.
- 7 Q. This is just your general understanding
- 8 of marketing of product period?
- 9 A. Yes.
- 10 Q. And then there is a statement in there:
- 11 Over the years consumer preference for cigarettes
- 12 have changed dramatically. For example."
- 13 How did you obtain that information?
- 14 A. Again, from conversations, from reading
- 15 reports, from having lived through the history of
- 16 some of the changes, from knowing that filters only
- 17 became important in the fifties.
- 18 Q. How did you know that?
- 19 A. Anecdotally and I'm sure from reading
- 20 some reports.
- Q. Internal documents?

- 1 A. Yes.
- Q. Do you know --
- 3 A. And external publicly available
- 4 documents.
- Q. Why would it be that consumers, or what
- 6 was your understanding as to why consumers in the
- 7 fifties had a preference for filter cigarettes?
- 8 A. I don't think in the fifties they did
- 9 have a preference for filtered cigarettes.
- 10 Q. Okay. When did they develop a
- 11 preference for filter cigarettes?
- 12 A. I think it probably started in the mid
- 13 to late fifties and gained momentum over time.
- 14 Q. What was it that changed consumer
- 15 preference?
- 16 A. I think in large part, it was in
- 17 response to publicity about the alleged dangers of
- 18 cigarette smoking.
- 19 Q. People thought by using filter
- 20 cigarettes they would be avoiding the potential
- 21 hazards or reducing the potential hazards that they

THE REALTIME REPORTING GROUP, INC.

- 1 became aware of through public press or whatever?
- A. I can't state what was in their mind,
- 3 but I think it is reasonable that they felt they
- 4 were reducing any risk that they had heard about,
- 5 by reducing the tar and nicotine and the vehicle to
- 6 do that was through filtration.
- 7 Q. You say you can't state what was in
- 8 their mind. You are aware that research has been
- 9 done by the marketing department and people they
- 10 have hired on the outside, that is the marketing
- 11 department of Lorillard, as to how people perceive
- 12 their cigarettes, correct?
- 13 A. I had no knowledge of what people were
- 14 thinking and doing in the fifties. I was a
- 15 teenager.
- 16 Q. You don't know what it was about the
- 17 filter cigarettes that were motivating people to
- 18 change from unfiltered to filtered cigarettes.
- 19 A. As I previously stated to you, I think
- 20 it was for reduction of tar and nicotine.
- 21 Q. What was the motivating force to reduce

THE REALTIME REPORTING GROUP, INC.

- the tar and nicotine?
- A. My opinion would be it was reports on
- 3 the hazards of smoking or that cigarettes with
- 4 lower tar and nicotine were preferable to
- 5 cigarettes with higher tar and nicotine.
- 6 Q. From a safety perspective, from a health
- 7 perspective?
- 8 A. In broad terms, from a health
- 9 perspective.
- 10 Q. And Lorillard addressed its marketing
- 11 plan to those health concerns; did they not?
- 12 A. Lorillard addressed their marketing
- 13 plans to their estimates of what consumer
- 14 preference would be.
- 15 Q. Getting back to the question, that
- 16 related to health concerns, correct?
- 17 A. That related to a demand for lower tar
- 18 and nicotine cigarettes or for filter cigarettes.
- 19 Q. Which related to health concerns, did it
- 20 not?
- MR. LONG: Are you saying that Lorillard

THE REALTIME REPORTING GROUP, INC.

- 1 marketing related to health concerns or that the
- 2 consumer preference related to health concerns?
- MR. EDELL: You can work it from either
- 4 end.
- 5 MR. LONG: If you want him to answer the
- 6 question, you have to tell him which direction.
- 7 MR. EDELL: He had no problem answering
- 8 the question before you said that.
- 9 MR. LONG: There was a long pause, he
- 10 was thinking.
- MR. EDELL: You can think as long as you
- 12 like.
- Q. The question is whether or not the
- 14 marketing plan by Lorillard, insofar as its
- 15 long-term approach to the marketing of its product,
- was geared to the health, concerns of consumers?
- 17 A. It was certainly geared to consumer
- 18 preferences and what they would ask them for, which
- 19 I already stated I think the consumers felt that
- 20 there was a health advantage to them smoking
- 21 reduced tar or filtered cigarettes.

THE REALTIME REPORTING GROUP, INC.

```
1 Q. Did Lorillard attempt to convey to its
```

- 2 consumers the fact that there were health benefits
- 3 to smoking their products?
- A. Not to my knowledge. The only things I
- 5 remembered, the advertisement stated that these
- 6 cigarettes had lower tar.
- 7 Q. You don't remember that being part of
- 8 their marketing program, to convey to their
- 9 consumers that their products from a health
- 10 perspective were better than other products on the
- 11 market?
- 12 A. Not during my tenure, no.
- MR. LONG: I think you mean --
- 14 Q. You say not during your tenure, you mean
- 15 not during the years you were employed by
- 16 Lorillard?
- 17 A. Correct.
- 18 Q. You are not familiar with the marketing
- 19 research with respect to True cigarettes?
- 20 A. Not at its inception, it predated my
- 21 joining the company.

- 1 Q. You didn't review that information?
- 2 MR. LONG: When?
- 3 MR. EDELL: At any point in time. You
- 4 never reviewed that information?
- 5 A. I may have. I don't recall having
- 6 reviewed it. I was not in marketing.
- Q. When you were in marketing, was there
- 8 any attempt by Lorillard, with respect to, let's
- 9 say True, to convey to consumers, that there were
- 10 health benefits to smoking true cigarettes?
- 11 A. Not to my knowledge.
- Q. Were you aware that True cigarette
- 13 smokers viewed True cigarettes as a more healthy
- 14 cigarette than others on the market?
- 15 A. It is my personal opinion that smokers
- 16 of all ultra-low tar cigarettes by and large felt
- 17 that that was the case for their cigarettes,
- 18 including the smokers of True.
- 19 Q. I don't want to know your personal
- 20 opinion. I want to know your opinion as a person
- 21 with Lorillard for almost 30 years.

THE REALTIME REPORTING GROUP, INC.

- 1 MR. LONG: He already testified that he
- 2 is not knowledgeable about the True advertising.
- 3 You asked him a question and he said, yes, that is
- 4 my perception with all low-tars including True.
- 5 You may not like the answer, but that doesn't mean
- 6 you have to go back and try to keep getting an
- 7 answer that you do like.
- 8 Q. Is it your testimony that you have never
- 9 seen the marketing and advertising proposals with
- 10 respect to True cigarettes?
- 11 A. Absolutely not. Absolutely it is not
- 12 true that I said I have never seen any marketing
- 13 and advertising of True
- MR. EDELL: That was the inference that
- 15 counsel suggested.
- 16 MR. LONG: No. You are talking about
- one time period when he said he didn't.
- 18 O. Let's make sure we are all on the same
- 19 plate. You are familiar with marketing and
- 20 continuing research done with respect to True
- 21 cigarettes that related to Lorillard's consumers'

- 1 perception that True was a safe cigarette,
- 2 correct?
- A. No. We didn't investigate issues of
- 4 safety.
- Q. You are as sure of that as everything
- 6 else you have said here today; is that correct?
- 7 MR. LONG: That he hasn't seen them?
- 8 MR. EDELL: That we didn't investigate
- 9 issues of perception of safety by your consumers.
- 10 A. I didn't say perceptions. I said we
- 11 didn't investigate safety issues.
- 12 Q. We have established that you didn't --
- 13 A. I earlier stated that I felt that
- 14 smokers of low tar cigarettes had a perception that
- 15 they were safer.
- 16 Q. My question was: Was there research
- 17 conducted by Lorillard or at their behest that
- 18 investigated the perception of their customers with
- 19 respect to the safety of any of their products?
- 20 A. I don't recall any research related to
- 21 safety.

THE REALTIME REPORTING GROUP, INC.

- 1 Q. Not related to safety. I want to make
- 2 sure we understand.
- 3 A. I am misunderstanding you then.
- 4 Q. Not whether or not Lorillard did any
- 5 research to see whether their product was safe.
- 6 Whether or not they did marketing research to
- 7 determine how their consumers perceived their
- 8 products with respect to the issue of health and
- 9 safety.
- 10 A. I think I have answered that. I said I
- 11 don't know of any research that addressed that
- 12 issue in that way.
- 13 Q. You are as sure of that as you are
- 14 everything else you have said today; is that
- 15 correct?
- 16 A. Yes. I'm sure of it.
- 17 Q. I just wanted to make sure.
- 18 Did any research that was conducted by
- 19 Lorillard or any of its agents, outside agencies,
- 20 relate to why people used, for example, true
- 21 cigarettes?

- 1 A. Yes.
- Q. Did it have anything to do with their
- 3 perception of a cigarette?
- 4 A. Yes.
- 5 Q. With their perception of whether or not
- 6 it was or was not more or less advantagous to use
- 7 True from a health perspective?
- 8 A. I don't think from a health
- 9 perspective. They were aware it was an ultra low
- 10 tar and nicotine cigarette, another group of True
- 11 smokers, when they were asked, another reason they
- 12 liked it was the construction of the filter.
- 13 Q. Did True cigarette smokers view True as
- 14 an alternative to their quitting, as a safer
- 15 alternative between continuing to smoke other
- 16 brands versus True cigarettes?
- 17 MR. LONG: I'm going to let him answer.
- 18 Could you explain how that relates to the class
- 19 issues we are here on? You are at some point
- 20 certainly entitled to merits. But under the case
- 21 management order, we are to be addressing class

- l certification issues. We have the affidavit on the
- 2 design issues, and you are talking about something
- 3 else now.
- 4 MR. EDELL: It may relate to whether or
- 5 not there are additional ways of defining the
- 6 class, whether there are subclasses.
- 7 MR. LONG: Really?
- 8 MR. EDELL: Really.
- 9 A. I am not aware of any research in that
- 10 area. I do recall an old ad that had the word
- 11 "quitting" in it related to True. I don't
- 12 remember the specifics of it. I'm not sure of the
- 13 time frame. I think it was pretty old.
- 14 Q. You weren't aware that the research
- 15 related to True cigarette smokers indicated the
- 16 inability to discontinue the use of cigarettes and
- 17 therefore they used True as an alternative to
- 18 quitting?
- 19 A. Repeat that, please?
- 20 O. You weren't aware that the research
- 21 related to True cigarette smokers indicated the

- 1 inability, their inability to discontinue the use
- 2 of cigarettes and therefore they used True as an
- 3 alternative to quitting?
- 4 A. I'm not aware of research in that
- 5 regard, no.
- 6 Q. What brands were manufactured by
- 7 Lorillard during the time period you were there,
- 8 and for what period of time each of those brands
- 9 manufactured?
- 10 A. I don't know if I can give you a
- 11 complete list. I will talk until I run out of
- 12 gas.
- MR. LONG: You want to refresh your
- 14 recollection from one of the documents we have
- 15 here?
- 16 MR. EDELL: I think he is suggesting
- 17 that you look at the document.
- MR. LONG: I'm saying if you want an
- 19 accurate list, he can look at a document.
- 20 THE WITNESS: I don't think a document
- 21 would be all-encompassing.

THE REALTIME REPORTING GROUP, INC.

 \bigcirc

- 1 MR. LONG: We can start with the
- 2 Maxwell.
- 3 MR. GUSTAFSON: One is Lorillard
- 4 specifically.
- 5 Q. There is a typed list of Lorillard
- 6 Tobacco Company brands and brand styles 1960 to
- 7 present. Did you prepare that list?
- 8 A. No. I did not.
- 9 Q. Who prepared that list?
- MR. LONG: I think it is an
- interrogatory response that was given recently.
- MR. EDELL: I'm asking the witness
- 13 whether he knows?
- 14 A. I just said I did not, and I don't know.
- Q. You don't know who prepared it?
- 16 A. No.
- Q. Did you rely upon that list in any way
- 18 to formulate your opinions in this case?
- 19 A. No, sir.
- MR. EDELL: Why don't we mark this as
- 21 Exhibit 89? We'll mark the list your counsel says

- 1 is part of answers to interrogatories --
- MR. LONG: Your subpoena duces tecum
- 3 asked for a list of brands or something, and that's
- 4 what this is.
- 5 MR. EDELL: We'll mark this Maxwell
- 6 publication you have given us as 90.
- 7 Q. I'm going to show you Plaintiff's
- 8 Exhibit 90. Where did you get that?
- 9 A. From my personal files in my office.
- 10 Q. And does that reflect the various brands
- 11 manufactured by Lorillard over the years?
- 12 A. It did not include some brands that were
- 13 test marketed. It includes the brands that were
- 14 sold nationally.
- 15 Q. Does it also indicate for what years
- 16 they were sold nationally?
- A. I can't find the Lorillard brands on
- 18 this. That's the competitive companies.
- 19 MR. LONG: Did you bring the original
- 20 with you?
- THE WITNESS: Yes.

- 1 MR. LONG: Get it out.
- MR. LONG: You want to put the sticker
- 3 on this and we'll copy it and put it in?
- 4 MR. EDELL: Fine. We'll just need
- 5 another 89.
- 6 (Whereupon, Plaintiff's Deposition
- 7 Exhibit No. 89, brand list, marked.)
- 8 (Whereupon, Plaintiff's Deposition
- 9 Exhibit No. 90, brand list, marked.)
- 10 Q. The document marked as 89, that reflects
- 11 the various brands manufactured by Lorillard in the
- 12 years they were manufactured; is that correct?
- MR. LONG: For a certain time period.
- 14 Q. For what time period?
- 15 A. It goes back 65 years, as I recall, up
- 16 through 1990, I believe. From 1925 to 1989.
- 17 Q. I'm sorry, that's 90, the document we're
- 18 talking about is Plaintiff's Exhibit 90.
- 19 A. Yes. It is Exhibit 90.
- Q. Thank you.
- A. It covers the time period 1925 to 1989.

- 1 I did refer to it in the preparation of my
- 2 affidavit.
- Q. Does that also list the percentage of
- 4 the market that these various cigarettes had?
- 5 A. Yes.
- Q. Do you have any reason to believe that
- 7 the information contained in this is not accurate?
- 8 A. No. I think it would be accurate.
- 9 There could be an occasional typo in there, but it
- 10 should be accurate.
- 11 Q. In your review of the materials, you
- 12 didn't see any obvious errors, did you?
- A. No. But I didn't look at every market
- share for every year, but, no, I saw no errors.
- Q. Did you look at Lorillard's market share
- 16 for the various products?
- 17 A. Yes. I did.
- Q. Did you see any errors with respect to
- 19 the Lorillard brands?
- 20 A. If I did, I didn't focus on that. I was
- 21 interested in seeing when brands were introduced

THE REALTIME REPORTING GROUP, INC.

and what time frame, for the purposes of the

- 2 statements I put in here.
- Q. Have there been major brands of
- 4 Lorillards over the years?
- 5 A. Yes.
- 6 Q. How did you define major brand?
- 7 A. It is very important to Lorillard as a
- 8 portion of our sales, they may not be major in
- 9 terms of the total marketplace.
- 10 Q. What percentage of your overall
- 11 cigarette sales would you consider before a product
- 12 became a major brand? In other words, let's say is
- 13 it a product that accounts for 30 percent of their
- 14 cigarette sales or 40 percent or 20 percent or 10
- 15 percent?
- 16 A. Of Lorillard's sales?
- 17 Q. Yes.
- A. All the brands that we marketed, we
- 19 consider to be important.
- Q. Major, talking about major. Every brand
- 21 is important.

24. 80 7 THE REALTIME REPORTING GROUP, INC. ∞

- 1 A. In our view, at least my personal view,
- 2 we had three major brand families.
- Q. What are they?
- A. Kent, Newport and Old Gold.
- 5 Q. What percentage of sales could be
- 6 attributed to those three major brand areas?
- 7 MR. LONG: When?
- 8 MR. EDELL: 1985 to 1990?
- 9 A. It would vary over time, at one point,
- 10 Old Gold accounted for up to 90 percent of our
- 11 sales.
- 12 Q. Up to what point in time?
- A. You want me to refer to the document for
- 14 an answer or give you an approximation?
- 15 Q. If you can readily do that, that would
- 16 be helpful.
- 17 A. Old Gold was our dominant brand through
- 18 1956, it would appear to me.
- 19 Q. When you say "dominant brand", what
- 20 percentage are you referring to?
- MR. LONG: Of Lorillard sales?

- 1 A. Of Lorillard sales?
- Q. Yes.
- 3 A. Just a second. In excess of 85 percent.
- Q. And then what became, Kent became a
- 5 bigger components?
- 6 A. Yes.
- 7 Q. Through what period of time?
- 8 A. From about 1957 -- from '59 to '66, Kent
- 9 represented more than 50 percent of our business.
- It fell from that from '67 on, but still
- 11 quite important up into the mid seventies.
- 12 Q. What filled up the shortfall from the
- 13 percentage point of view?
- 14 A. Newport and True for that period of
- 15 time.
- 16 O. They accounted for how much. Between
- 17 Newport, True and Kent, what percentage did those
- 18 three brands from 1957 to the present account for
- in terms of overall Lorillard sales?
- 20 A. Did you say from '67 to the present?
- 21 Q. Yes.

THE REALTIME REPORTING GROUP, INC.

```
1 A. Can I have a pencil?
```

- 2 O. Yes.
- A. I will do it for '67 and '77 if that is
- 4 acceptabale. If you want to take the time, I will
- 5 calculate it for every year.
- 6 MR. LONG: You realize he has to
- 7 calculate this based on numbers a year, you are
- 8 asking him to do some wild averaging of ten years.
- 9 MR. EDELL: I'm asking you to give me an
- 10 approximation between 10 percent, not to give -- I
- 11 don't want it out to the 14th decimal point.
- MR. LONG: He has to run the numbers to
- 13 see if there is a 10 percent difference between the
- 14 beginning and the end.
- 15 MR. EDELL: We were just given the
- 16 document that he has.
- 17 MR. LONG: Yes. What he has is what the
- 18 document says. To get the numbers you are asking
- 19 for, he has to do these calculations. That's all
- 20 I'm saying. We're all assuming he is doing the
- 21 calculations correctly and relying upon that.

```
MR. EDELL: He is the expert.
```

- MR. LONG: Didn't say he was an expert
- 3 in math.
- 4 MR. EDELL: He is the expert in terms of
- 5 the class action.
- 6 MR. LONG: Loan long I'm saying bear in
- 7 mind he is working with the numbers on the Maxwell
- 8 chart.
- 9 MR. EDELL: Which is a reliable source.
- MR. LONG: You get my point, he has to
- 11 do some math.
- MR. EDELL: I got it.
- 13 A. Okay. In 1977, Newport represented
- 14 approximately 15 percent of our business, Kent
- 15 approximately 60 percent of our business, True
- 16 approximately 16 percent of our business and Old
- 17 Gold approximately 10 percent of our business.
- 18 That adds up to 91 percent, to that is within the
- 19 10 percent you asked for. That is '67. Do you
- 20 want to jump now to '77?
- Q. Fine with me, unless you think there

THE REALTIME REPORTING GROUP, INC.

- would be some substantial benefit for us doing it
- 2 by five-year versus ten years.
- MR. LONG: How is He going to know that
- 4 when he doesn't know the purpose of your question?
- 5 Q. I will tell you the purpose of the
- 6 question. The purpose of the question is to see
- 7 whether or not, in fact, the overwhelming
- 8 percentage of the sales were restricted over the
- 9 entire period of time to four brands of
- 10 cigarettes: Kent, True, Newport and Old Gold.
- 11 MR. LONG: For purposes of
- 12 clarification, when you did these numbers, is that
- 13 every style in the brand family?
- 14 THE WITNESS: Yes. I have lumped them.
- 15 MR. EDELL: That's fine with me.
- 16 A. Yes. Those four brands would account
- 17 for the majority of our sales over this whole time
- 18 period. The mix within those would vary.
- 19 Q. When you say the majority, we are
- 20 talking about close to 90 percent, 85 to 90
- 21 percent?

THE REALTIME REPORTING GROUP, INC.

- 1 A. My estimate would be in excess of 75
- 2 percent, without doing all the calculating.
- 3 Perhaps higher.
- Q. When you say "perhaps higher" do you
- 5 believe it is greater than 75 percent, any years
- 6 you believe it was less than that?
- 7 A. No. I believe it will always be at
- 8 least 75 percent, probably more.
- 9 Q. At least 80 percent?
- 10 A. Sir, if you keep doing this, I have to
- 11 go back and recalculate the numbers. 80 percent,
- 12 plus or minus ten, certainly.
- 13 Q. Thank you. Maybe we can do it the other
- 14 way. Have there been any brands that have
- 15 accounted for more than five percent of Lorillard
- 16 sales over all of these years, other than the four
- 17 general brand areas that we have talked about?
- 18 MR. LONG: Again, you mean a brand
- 19 family?
- MR. EDELL: A brand family.
- A. I don't think there would be any more

1 than 10 percent. I am not sure of your question of

- 2 five percent.
- 3 Q. Okay. Lorillard used these four
- 4 different categories or five different categories
- 5 that you have listed as a means to adjust the tar
- 6 and nicotine yields of cigarettes, is that correct,
- 7 in paragraph 8?
- 8 A. Would you repeat the question again,
- 9 Lorillard used what?
- 10 Q. These five various means by which to
- 11 adjust the tar and nicotine yields of its products?
- 12 A. What five variables?
- 13 Q. Reconstituted tobacco, extended
- 14 tobacco --
- A. Oh, A through E?
- 16 Q. Yes.
- 17 A. Yes.
- 18 Q. When was the first time they tried to
- 19 use any of these as a means to reduce overall tar
- 20 and nicotine? Was it filters, is that fair to
- 21 say?

- 1 A. That's fair to say.
- Q. That was in the --
- A. Mid 1950's, I believe.
- Q. From 19 -- the mid 1950's, to the early
- 5 sixties, was that the only means that was used by
- 6 Lorillard to adjust the tar and nicotine yield of
- 7 its products?
- 8 A. Repeat the time frame, please, you said
- 9 from the mid 50's --
- 10 Q. The mid 1950's to the early 1960's, was
- 11 that the only means, again, referring to the use of
- 12 filters?
- 13 A. I think that's fair to say.
- 14 Q. Then in the early 1960's, they added
- 15 reconstituted tobacco as a means to adjust the tar
- 16 and nicotine yield; is that correct?
- 17 A. I don't believe it was the early
- 18 sixties.
- 19 Q. I thought that's what you said in your
- 20 affidavit, to I thought it was correct.
- 21 A. Yes, it is.

THE REALTIME REPORTING GROUP, INC.

S

```
1 Q. Lorillard did not begin using
```

- 2 reconstituted tobacco until the early 1960's; is
- 3 that what that says?
- 4 A. That's what it says.
- Q. Where did you get that information?
- 6 A. From our reports, internal documents.
- 7 Q. Do they continue to use reconstituted
- 8 tobacco today?
- 9 A. Correct.
- 10 Q. And then they added in the mid 1960's, a
- 11 change in the ventilation design to adjust the tar
- 12 and nicotine yields?
- 13 A. It was the sixties when we started
- 14 incorporating ventilation, yes.
- 15 Q. In approximately 1966, you say?
- 16 A. Yes.
- Q. And then in 1972, you added -- they
- 18 added expanded tobacco as a means to adjust the tar
- 19 and nicotine yield, correct?
- 20 A. That's one result of expanded tobacco,
- 21 yes.

- 1 Q. That is the reason they used the
- 2 extended tobacco, to adjust the tar and nicotine
- 3 yields?
- 4 A. I believe the main thing at the time was
- 5 cost savings. I believe that's stated in here as
- 6 well, yes.
- 7 Q. To it wasn't primarily a means to adjust
- 8 the tar and nicotine; is that right?
- 9 A. I don't believe it was.
- 10 Q. To is it fair to say that all of these
- 11 different changes that you say are incorporated in
- 12 the various designs was simply a means, insofar as
- 13 what is relevant here, is simply a means to adjust
- 14 the tar and nicotine yields?
- MR. LONG: I object. Marc, he testified
- 16 the main use of extended tobacco was something and
- 17 now you are saying it was the means.
- 18 Q. Is there anything else other than these
- 19 five different design changes that Lorillard
- 20 employed to change the tar and nicotine yield?
- 21 MR. LONG: Object again. Now, you are

- saying or you are implying --
- 2 MR. EDELL: I agree with you.
- Q. Is there anything other than these five
- 4 design changes that resulted in a change in the tar
- 5 and nicotine yields of Lorillard products?
- 6 A. I don't think to. May I ask for a
- 7 five-minute break?
- 8 (Break.)
- 9 MR. EDELL: I'm trying to see what I can
- 10 ask you to use up the time that doesn't relate to
- 11 these documents I can't ask you about, Doctor. To
- 12 bear with me.
- With the understanding we have agreed
- 14 that we will come back and finish his deposition
- when and if there is a protective order in place,
- 16 is that correct, Mr. Long?
- MR. LONG: When do you want to do that?
- 18 Let me ask you that. We have no problem producing
- 19 him later on for a merits deposition.
- MR. EDELL: There are documents that
- 21 relate to not only merits but other issues, that

```
1 you object to my using during the course of this
```

- 2 deposition because we have not reached an accord on
- 3 a protective order, correct?
- 4 MR. LONG: Right.
- 5 MR. EDELL: I thought we agreed that we
- are going to try to iron out those differences. If
- 7 not, you will make an emergent application for a
- 8 protective order and we can continue this
- 9 deposition after the court or we resolve the issue
- 10 of protective orders. Am I incorrect?
- 11 MR. LONG: No. I was thinking you are
- 12 entitled to request that, and I'm not going to
- 13 object to that.
- MR. EDELL: Do we have an accord on that
- 15 issue?
- MR. LONG: Yes.
- 17 Q. Let's talk about your background. You
- 18 got your ABA from University of East Carolina in
- 19 1963?
- 20 A. My A.B.
- Q. What did you do after that?

- 1 A. I went to graduate school, Emory
- 2 University in Atlanta.
- 3 Q. For four years?
- 4 A. And three months.
- 5 Q. And three months. And you graduated
- 6 with a Ph.D. in chemistry, organic chemistry?
- 7 A. Yes.
- 8 Q. You immediately became the research
- 9 chemist at Lorillard?
- 10 A. Yes.
- 11 Q. What did you do?
- 12 A. Synthetic organic chemistry.
- Q. What does that mean?
- 14 A. I was synthesizing compounds that the
- 15 company had interest in.
- 16 Q. Synthesizing compounds that the company
- 17 had interest in, synthesizing what compounds?
- 18 A. Specifically, a compound known as PMO in
- 19 the early days when I first joined the company.
- Q. What is PMO?
- 21 A. Phenylmethyl oxadiazole.

1 Q. What was the purpose of your research?

- 2 A. It was my job to produce the chemical,
- 3 the compound, it was being used by others for
- 4 testing.
- Q. Can you explain to me what you mean?
- 6 What context were you introducing the chemical
- 7 compound?
- 8 A. I was preparing it for others for use in
- 9 testing they were doing.
- 10 Q. What type of testing?
- 11 A. I'm not expert in the area, but I know
- 12 the compound was added to cigarettes, and if I
- 13 recall correctly, it was thought that it had an
- 14 effect on ciliostatic activity.
- 15 Q. That is the lung's mechanism --
- 16 A. The little hair follicles as I
- 17 understand it. I don't know much about that area.
- 18 Q. Is that for product development?
- A. Not at that time, I don't think. I
- 20 think it was for testing to see if, in fact, it did
- 21 have an effect on ciliostatic activity.

THE REALTIME REPORTING GROUP, INC.

- 1 Q. Did it?
- 2 A. I don't know. It was purported to have,
- 3 but I was a new chemist at the time, and it was my
- 4 job to produce it and purify it and hand it over to
- 5 somebody else.
- Q. They didn't know let you know what the
- 7 results were?
- 8 A. It wasn't an issue of that.
- 9 Q. Okay.
- 10 A. I don't know the results. I know there
- 11 were consultants working on the project, but I
- 12 didn't know them, I didn't talk with them.
- Q. Who were the consultants?
- 14 A. If I remember correctly, their names
- 15 were Dahlham and Reilander. I believe they were in
- 16 Sweden.
- 17 Q. Did you have any contact with those
- 18 individuals?
- 19 A. I don't believe to. May have been
- 20 introduced to them in passing. No discussions with
- 21 them.

THE REALTIME REPORTING GROUP, INC.

- 1 Q. For what period of time did you do this
- 2 research on these phenyls?
- A. Best of my recollection, the two years
- 4 that I was in the research department, when I
- 5 joined the company.
- 6 Q. 1970 through 1972, you were a supervisor
- 7 of product development?
- 8 A. Yes.
- 9 Q. What did that entail?
- 10 A. That entailed product development, as we
- 11 have talked about today, but at that point, I was
- 12 just starting to learn about blending, flavoring,
- 13 filters, supervising a group of chemists already
- 14 employed in product development.
- 15 Q. '72 to '77 you were manager of product
- 16 development international?
- 17 A. Yes, sir.
- 18 Q. Does that mean you didn't have any
- 19 involvement with domestic activities at all?
- 20 A. It was not one of my responsibilities,
- 21 but I was based in Greensboro and in the R and D

- 1 center, to I had familiarity with the product
- 2 development.
- 3 Q. But you didn't have any responsibility
- 4 for any domestic branch; is that correct?
- 5 A. That's correct.
- 6 Q. '77 through '83, you were the manager of
- 7 operations and research planning?
- 8 A. Yes, sir.
- 9 Q. What does that mean?
- 10 A. Essentially, I moved from the R and D
- 11 center to the manufacturing center. I essentially
- 12 acted as a liaison between R and D, manufacturing,
- 13 marketing and the leaf department.
- 14 Q. And what did you do?
- 15 A. Project scheduling, keeping the
- 16 marketing people abreast of timings when new
- 17 equipment was needed to produce a new brand, when
- it would be delivered and installed, planning if
- 19 you want production requirements.
- 20 Q. Did you have anything to do with design
- 21 of cigarettes, domestic cigarettes?

A. It was not a key responsibility, but I

- 2 still interfaced with the product development
- 3 group.
- Q. Whose responsibility was it for the
- 5 design of domestic cigarettes from 1972 to 1983 at
- 6 Lorillard?
- 7 A. The person whose title was supervisor
- 8 product development, which was mine until 1972, was
- 9 Al Hudson.
- 10 Q. Is he no longer with the company?
- 11 A. He is deceased.
- 12 Q. That's through '72. What about '72
- 13 through '77?
- 14 A. No. That was from '72 forward for some
- 15 years.
- 16 Q. Mr. Hudson?
- 17 A. Yes.
- 18 Q. And then in '83, you became director of
- 19 marketing research, correct?
- 20 A. Yes.
- Q. Did you design cigarettes during that

THE REALTIME REPORTING GROUP, INC.

- 1 period of time?
- A. I would say no.
- Q. Did you ever design a cigarette?
- 4 A. Yes.
- Q. I asked you that, didn't I?
- A. Yes.
- 7 Q. What cigarette did you design?
- MR. LONG: You asked him had he worked
- 9 on various cigarette brands.
- 10 Q. What cigarette did you design?
- 11 A. I'm not sure I designed one in its
- 12 entirety by myself. We work as a group in product
- 13 development. I had major input into the design of
- 14 several products.
- Q. What products?
- 16 A. Kent Golden Lights, Kent III.
- Q. Anything else?
- 18 MR. LONG: Isn't this -- didn't we go
- 19 through in this morning?
- MR. GUSTAFSON: Yes.
- MR. EDELL: I don't remember asking

THE REALTIME REPORTING GROUP, INC.

- 1 specifically about these.
- MR. LONG: You got him to list the
- 3 cigarettes he had input into the development of.
- 4 MR. EDELL: I thought it was a general
- 5 question of what did he participate in the
- 6 revisions of or the design? That was the question,
- 7 but I'll check the notes.
- 8 A. My recollection is when you pursued it
- 9. this morning, I said I was involved to some degree
- 10 with every brand that was designed from '70 onward.
- 11 Q. To some degree either in the context of
- 12 marketing research?
- MR. LONG: He said designing.
- Q. From '70 onward you were involved to
- 15 some degree in every product manufactured by
- 16 Lorillard; that is your testimony?
- 17 A. Probably not every brand, but most of
- 18 the brands. I still had an ongoing involvement.
- 19 Q. Were you involved from the marketing
- 20 perspective?
- 21 A. No. Also from the development

THE REALTIME REPORTING GROUP, INC.

```
1 perspective.
```

- Q. When was the last time you were involved
- 3 in the development perspective?
- 4 A. The last time?
- 5 Q. From 1992 to the present, you were
- 6 involved in development, right?
- 7 A. Yes, but from 1970 to present, I have
- 8 had some involvement. It is varied over time.
- 9 Q. How much involvement did you have, for
- 10 example, when you were director of marketing
- 11 research from 1983 to 1992, in the design of
- 12 cigarettes?
- 13 A. Much less than when I was based in
- 14 Greensboro.
- 15 Q. What was it, to we can get a better
- 16 handle on this?
- 17 A. I'm sure from time to time, I acted as
- 18 an internal consultant to people in product
- 19 development. I maintained a relationship with the
- 20 people in product development. I knew the
- 21 parameters that they were trying to develop, to I

THE REALTIME REPORTING GROUP, INC.

82

- 1 am sure I discussed with them ways to achieve the
- 2 intended result.
- But, no, it was not my primary
- 4 responsibility during that time frame.
- Q. When was it your primary
- 6 responsibility?
- A. Certainly from 1992 to present, but from
- 8 '70 to '72 and from '92 to present.
- 9 MR. LONG: '70 to '72 or '70 to '82?
- 10 A. '70 to '72, to I was in foreign
- 11 development, to though domestic was not my primary,
- 12 I had some involvement.
- MR. EDELL: Subject to my asking
- 14 questions that relate to these documents, I have
- 15 nothing further at this time.
- MR. LIPSON: Thank you.
- 17 (Discussion off the record.)
- 18 EXAMINATION BY MR. LONG:
- 19 Q. Dr. Jones, I have a few very brief
- 20 questions to ask, I think. Number one, if I can
- look back at what is marked as Plaintiff's

- 1 Deposition Exhibit No. 88. If you will look at the
- 2 cover memo attached to that, can you read into the
- 3 record the second sentence of that first
- 4 paragraph?
- 5 A. Although most of the material --
- 6 MR. EDELL: He just asked you whether
- 7 you could.
- 8 THE WITNESS: Yes. I can.
- 9 MR. EDELL: Thank you. I want to make
- 10 sure we're being careful here.
- 11 O. Read it.
- 12 A. Although most of the material is fairly
- 13 recent, I'm not sure what is relevant.
- Q. What does that mean to you?
- 15 A. It means I did my best to report what
- 16 was in all this literature and I'm not an expert in
- 17 that area.
- 18 Q. Mr. Edell asked you earlier this
- 19 morning, seems like hours ago, about certain
- 20 chemicals which were in the particulate matter of
- 21 cigarette smoke; do you recall that?

- 1 A. Yes, sir.
- Q. I think at times there was reference to
- 3 these chemicals being carcinogens, and what I will
- 4 ask you is: Do you have a professional opinion, an
- 5 expert opinion, as to whether those chemicals are
- 6 carcinogens?
- 7 A. I'm not an expert in that area. I have
- 8 read where some of these chemicals are reported to
- 9 be carcinogens, cigarette smoke, they are not in
- 10 very high levels.
- 11 Q. At what levels are these chemicals in
- 12 cigarette smoke?
- 13 A. I can't recall with certainty, some are
- 14 recorded in parts per billion, some in nanograms.
- Q. Even though you are dealing with trace
- 16 amounts, does the amount of these chemicals that
- 17 Mr. Edell mentioned, do they vary from cigarette
- 18 brand to cigarette brand?
- 19 A. My best estimate is only with the
- 20 difference in tar deliveries. Generally, I would
- 21 think that the higher tar cigarette would have more

THE REALTIME REPORTING GROUP, INC.

- 1 of these than a low-tar cigarette, only in that
- 2 sense.
- 3 Q. You talked a bit this morning with
- 4 Mr. Edell about the nicotine enrichment program.
- 5 Can you recall that?
- 6 A. I recall parts of that.
- 7 Q. To the best of your knowledge, was any
- 8 of the technology that Lorillard investigated in
- 9 the nicotine enrichment program ever used in a
- 10 cigarette that wastest marketed?
- 11 A. Not to my knowledge.
- 12 Q. Was any of the technology that Lorillard
- 13 explored in the nicotine enrichment program ever
- 14 used in a cigarette that Lorillard commercially
- 15 marketed?
- 16 A. Not to my knowledge.
- MR. LONG: That's all I have.
- 18 EXAMINATION BY MR. EDELL:
- 19 Q. Dr. Jones, during the years 1972 through
- 20 1977, you told us that you were not involved in the
- 21 design of domestic cigarettes; is that correct?

THE REALTIME REPORTING GROUP, INC.

- A. I said that was not one of my primary
- 2 responsibilities.
- 3 Q. You were involved in the design?
- 4 A. To some degree.
- 5 Q. From 1983 to 1992, were you involved in
- 6 all of the components of each of the cigarettes?
- 7 Were you aware of each of the components of each of
- 8 the cigarettes manufactured by Lorillard?
- 9 MR. LONG: You mean components, you
- 10 don't mean just ingredients? You mean design
- 11 parameters as well.
- 12 Q. Everything put in each of the
- 13 cigarettes.
- 14 A. No. I would not be aware of everything
- 15 that was put in each one of the cigarettes.
- 16 Q. Lorillard could have put any number of
- 17 substances in any of the cigarettes and would you
- 18 not have been aware of it, correct?
- 19 A. Certainly correct. I don't like the way
- 20 you asked the question, but its certainly correct.
- Q. Then it must have been a good question.

- 1 A. I don't think to. There is an
- 2 implication there that I didn't mean to be
- 3 responding to.
- Q. Other than the documents that have been
- 5 produced here by your counsel, did you review any
- 6 other documents upon which you relied for the
- 7 statements contained in your affidavit?
- 8 A. No, sir.
- 9 Q. You don't intend to rely on any
- 10 additional documents at any later juncture; is that
- 11 correct?
- 12 A. I don't think I'm willing to answer that
- 13 yet. I don't know.
- Q. Well, certainly, if the witness is going
- 15 to be shown additional documents, we would be
- 16 entitled to be advised of that.
- MR. LONG: Certainly, and depending upon
- 18 what documents you plan to use, if there is
- 19 something that Dr. Jones needs to refer to to get
- 20 the full complete story on it, that may well
- 21 happen.

1	MR. EDEBLI: Okay.
2	MR. LONG: But I don't think, insofar as
3	his opinion in the affidavit, I have no plans and I
4	think he has no plans to look at additional
5	materials to support what he has put in his
6	affidavit, but if he needs to respond to something
7	you bring up in a document it may well be necessary
8	to show him something else. That is all I'm
9	saying.
10	MR. EDELL: I have nothing further at
11	this juncture, again, with the caveat.
12	Again, we are going to mark the
13	documents he produced individually. Okay.
14	(Examination suspended 3:05 p.m.)
15	
16	(Whereupon, Plaintiff's Exhibit No.
17	91, letter dated March 3, 1997 from Brown to Jones
18	was marked for identification.)
19	(Whereupon, Plaintiff's Exhibit No.
20	92, letter to Honorable Warren G. Magnuson, was
21	marked for identification.)

THE REALTIME REPORTING GROUP, INC. $\frac{80}{3}$

 ∞

```
1
                     (Whereupon, Plaintiff's Exhibit No.
 2
     93, current cigarette brands as of 3/96, was marked
     for identification.)
 3
                     (Whereupon, Plaintiff's Exhibit No.
 4
 5
     94, notice of deposition, was marked for
     identification.)
 6
                     (Whereupon, Plaintiff's Exhibit No.
 7
 8
     95, CV, was marked for identification.)
 9
                     (Whereupon, Plaintiff's Exhibit No.
     96, memorandum dated February 27, 1996, was marked
10
     for identification.)
11
                     (Whereupon, Plaintiff's Exhibit No.
12
13
     97, memo dated February 11, 1997, was marked for
     identification.)
14
15
                     (Whereupon, Plaintiff's Exhibit No.
16
     98, invoice dated 11/27/95, was marked for
17
     identification.)
                     (Whereupon, Plaintiff's Exhibit No.
18
     99, invoice dated 2/12/96, was marked for
19
     identification.)
20
21
                     (Whereupon, Plaintiff's Exhibit No.
```

```
1 100, invoice 97-03 dated April 2, 1997, was marked
 2 for identification.)
 3
 4
5
 6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
```

 ∞

2	BY	MR.	EDELL 5	
3			LONG 174	
4	ВЧ	MR.	EDELL 179	
5				
6				
7				
8				
9				
10				
11				
12				
13			•	
14				
15				
16				
17				
18				
19				
20				
21				

INDEX OF EXAMINATION

1

1			I	NDEX O	F EXHI	BITS				
2	No.	88,	literatu	ce rev	iew me	mo	· · · · ·	• • • •		106
3	No.	89,	brand lis	st						150
4	No.	90,	brand lis	st						150
5	No.	91,	letter da	ated M	arch 3	, 199	97 fr	om		
6	Brow	n to	Jones					• • • •		180
7	No.	92,	letter to	Hono:	rable	Warre	en G.			
8	Magn	uson	· · · · · · · · · · · · ·							180
9	No.	93,	current o	igare	tte br	ands	as o	f 3/	96	181
10	No.	94,	notice of	depo	sition					181
11	No.	95,	cv							181
12	No.	96,	memorandı	ım datı	ed Feb	ruary	27,	199	6	181
13	No.	97,	memo date	d Feb:	ruary	11, 1	997.			181
14	No.	98,	invoice	dated	11/27	/95				181
15	No.	99,	invoice o	lated :	2/12/9	6				181
16	No.	100,	invoice	97-03	dated	Apri	1 2,	199	7	181
17										
18										
19										
20										
21										

THE REALTIME REPORTING GROUP, INC. $\stackrel{\rightharpoonup}{\searrow}$